<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia - Hwang, EC - 2018 | Cochrane Library</title> <meta content="Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia - Hwang, EC - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007360.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia - Hwang, EC - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007360.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007360.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia" name="citation_title"/> <meta content="Eu Chang Hwang" name="citation_author"/> <meta content="Chonnam National University Medical School, Chonnam National University Hwasun Hospital" name="citation_author_institution"/> <meta content="urohwang@gmail.com" name="citation_author_email"/> <meta content="Shreyas Gandhi" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Jae Hung Jung" name="citation_author"/> <meta content="Mari Imamura" name="citation_author"/> <meta content="University of Aberdeen" name="citation_author_institution"/> <meta content="Myung Ha Kim" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Ran Pang" name="citation_author"/> <meta content="Guang An Men Hospital, China Academy of Chinese Medical Sciences" name="citation_author_institution"/> <meta content="Philipp Dahm" name="citation_author"/> <meta content="Minneapolis VA Health Care System" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD007360.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/10/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007360.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007360.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007360.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic alpha-Antagonists [adverse effects, *therapeutic use]; Benzilates [adverse effects, therapeutic use]; Drug Combinations; Ethamsylate [adverse effects, therapeutic use]; Indoles [adverse effects, therapeutic use]; Lower Urinary Tract Symptoms [*drug therapy, etiology]; Naphthalenes [adverse effects, *therapeutic use]; Piperazines [adverse effects, *therapeutic use]; Plant Extracts [adverse effects, therapeutic use]; Prostatic Hyperplasia [*complications]; Prostatism [*drug therapy, etiology]; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides [adverse effects, therapeutic use]; Tamsulosin [adverse effects, therapeutic use]; Urological Agents [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007360.pub3&amp;doi=10.1002/14651858.CD007360.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="77cjsSG8";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007360\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007360\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007360.pub3",title:"Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia",firstPublishedDate:"Oct 11, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007360.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007360.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007360.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007360.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007360.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007360.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007360.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007360.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007360.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007360.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2280 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007360.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-sec-0129"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-sec-0030"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-sec-0031"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-sec-0123"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/appendices#CD007360-sec-0134"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/table_n/CD007360StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/table_n/CD007360StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information#CD007360-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Eu Chang Hwang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information#CD007360-cr-0003">Shreyas Gandhi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information#CD007360-cr-0004">Jae Hung Jung</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information#CD007360-cr-0005">Mari Imamura</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information#CD007360-cr-0006">Myung Ha Kim</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information#CD007360-cr-0007">Ran Pang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information#CD007360-cr-0008">Philipp Dahm</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information/en#CD007360-sec-0139">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 October 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007360.pub3">https://doi.org/10.1002/14651858.CD007360.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007360-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007360-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007360-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007360-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007360-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007360-abs-0001" lang="en"> <section id="CD007360-sec-0001"> <h3 class="title" id="CD007360-sec-0001">Background</h3> <p>Benign prostatic hyperplasia (BPH) is a common condition in ageing men that may cause lower urinary tract symptoms (LUTS). Treatment aims are to relieve symptoms and prevent disease‐related complications. Naftopidil is an alpha‐blocker (AB) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting. This is an update of a Cochrane Review first published in 2009. Since that time, several large randomised controlled trials (RCTs) have been reported, making this update relevant. </p> </section> <section id="CD007360-sec-0002"> <h3 class="title" id="CD007360-sec-0002">Objectives</h3> <p>To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH.</p> </section> <section id="CD007360-sec-0003"> <h3 class="title" id="CD007360-sec-0003">Search methods</h3> <p>We performed a comprehensive search using multiple databases (the Cochrane Library, MEDLINE, Embase, Scopus, LILAC, and Web of Science), trials registries, other sources of grey literature, and conference proceedings with no restrictions on the language of publication or publication status up to 31 May 2018 </p> </section> <section id="CD007360-sec-0004"> <h3 class="title" id="CD007360-sec-0004">Selection criteria</h3> <p>We included all parallel RCTs. We also included cross‐over design trials.</p> </section> <section id="CD007360-sec-0005"> <h3 class="title" id="CD007360-sec-0005">Data collection and analysis</h3> <p>Two review authors independently classified and abstracted data from the included studies. We performed statistical analyses using a random‐effects model and interpreted them according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. Primary outcomes were urological symptom scores, quality of life (QoL) and treatment withdrawals for any reason; secondary outcomes were treatment withdrawals due to adverse events, acute urinary retention, surgical intervention for BPH, and cardiovascular and sexual adverse events. We considered outcomes measured up to 12 months after randomisation as short term, and later than 12 months as long term. We rated the certainty of the evidence according to the GRADE approach. </p> </section> <section id="CD007360-sec-0006"> <h3 class="title" id="CD007360-sec-0006">Main results</h3> <p>We included 22 RCTs with 2223 randomised participants across four comparisons for short‐term follow‐up. This abstract focuses on only two of four comparisons for which we found data since two comparators (i.e. propiverine and Eviprostat (phytotherapy)) are rarely used. One study comparing naftopidil to placebo did not report any relevant outcomes and was therefore excluded. There were no trials that compared to combination therapy with naftopidil or any 5‐alpha reductase inhibitors (5‐ARIs) to combination therapy with other ABs and any 5‐ARIs. </p> <p>All included studies were conducted in Asian countries. Study duration ranged from four to 12 weeks. Mean age was 67.8 years, prostate volume was 35.4 mL, and International Prostate Symptom Score was 18.3. We were unable to perform any of the preplanned subgroup analyses based on age and baseline symptom score. </p> <p><b>Naftopidil versus tamsulosin</b> </p> <p>Based on 12 studies with 965 randomised participants, naftopidil may have resulted in little or no difference in urological symptom score (mean difference (MD) 0.47, 95% confidence interval (CI) –0.09 to 1.04 measured on a scale from 0 to 35 with higher score representing increased symptoms), QoL (MD 0.11, 95% CI –0.09 to 0.30; measured on a scale from 0 to 6 with higher scores representing worse QoL), and treatment withdrawals for any reason (risk ratio (RR) 0.92, 95% CI 0.64 to 1.34; corresponding to 7 fewer per 1000 participants, 95% CI 32 fewer to 31 more). Naftopidil may have resulted in little to no difference in sexual adverse events (RR 0.54, 95% CI 0.24 to 1.22); this would result in 26 fewer sexual adverse events per 1000 participants (95% CI 43 fewer to 13 more). We rated the certainty of evidence as moderate for urological symptom score and low for the other outcomes. </p> <p><b>Naftopidil versus silodosin</b> </p> <p>Based on five studies with 652 randomised participants, naftopidil may have resulted in little or no difference in the urological symptom scores (MD 1.04, 95% CI –0.78 to 2.85), QoL (MD 0.21, 95% CI –0.23 to 0.66), and treatment withdrawals for any reason (RR 0.80, 95% CI 0.52 to 1.23; corresponding to 26 fewer per 1000 participants, 95% CI 62 fewer to 32 more). We rated the certainty of evidence as low for all these outcomes. Naftopidil likely reduced sexual adverse events (RR 0.15, 95% CI 0.06 to 0.42; corresponding to 126 fewer sexual adverse events per 1000 participants, 95% CI 139 fewer to 86 fewer). We rated the certainty of evidence as moderate for sexual adverse events. </p> </section> <section id="CD007360-sec-0007"> <h3 class="title" id="CD007360-sec-0007">Authors' conclusions</h3> <p>Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin. Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007360-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007360-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007360-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007360-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007360-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007360-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007360-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007360-abs-0004" lang="en"> <h3>Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia </h3> <p><b>Review question</b> </p> <p>What are the effects of naftopidil in men with bothersome urinary symptoms due to an enlarged prostate? </p> <p><b>Background</b> </p> <p>An enlarged prostate (called benign prostatic hyperplasia) can cause bothersome lower urinary tract symptoms such as having to urinate often during the day or at night, having a weak urine stream, and having the feeling of not emptying the bladder completely. A common reason for these complaints is an enlarged prostate, which is common in older men. Naftopidil is a medication that may help with these symptoms and possibly cause fewer unwanted effects than other medications used for this problem. In this review, we compared naftopidil to other medicines. </p> <p><b>Study characteristics</b> </p> <p>We included 22 studies with 2223 men. The average age was 68.0 years. These men had mostly symptoms rated as moderate or severe. </p> <p><b>Key results</b> </p> <p>Naftopidil may have had similar effects on urinary symptoms and QoL compared to tamsulosin and silodosin. In terms of unwanted effects, naftopidil may have had similar unwanted sexual side effects compared to tamsulosin but have fewer compared to silodosin. </p> <p><b>Reliability of the evidence</b> </p> <p>The reliability of evidence for most symptoms was low. This means that the true effect may be substantially different from what this review shows. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007360-sec-0129" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007360-sec-0129">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007360-sec-0193">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007360-sec-0129"></div> <h3 class="title" id="CD007360-sec-0130">Implications for practice</h3> <section id="CD007360-sec-0130"> <p>Based on moderate‐to‐low certainty evidence, the effect of naftopidil appears similar to tamsulosin with regards to urological symptom scores, quality of life, and sexual adverse events. </p> <p>Based on low‐certainty evidence, the effect of naftopidil appears similar to silodosin for urological symptom scores and quality of life. However, it probably has fewer sexual adverse events compared to silodosin based on moderate‐certainty evidence. This information is important for the counselling of sexually active men. </p> </section> <h3 class="title" id="CD007360-sec-0131">Implications for research</h3> <section id="CD007360-sec-0131"> <p>Our knowledge could be improved by focus on the following issues.</p> <p> <ul id="CD007360-list-0028"> <li> <p>Given that patients take alpha‐blockers for extended periods of time (typically years), there is a critical need for long‐term studies of safety and efficacy of naftopidil. Such studies would also help to inform the outcome of acute urinary retention and surgical interventions for benign prostatic hyperplasia. </p> </li> <li> <p>Several trials included in this review used suboptimal dose of naftopidil (25 mg) and silodosin (4 mg). This may result in an underestimate of both the beneficial effects and the potential adverse events. Unfortunately, we were unable explore this and other questions around possible subgroup effects (based on patient age and baseline International Prostate Symptom Score) in subgroup analyses. </p> </li> <li> <p>Most included studies had considerable methodological limitations. It would be preferable if future studies applied appropriate allocation concealment, blinding of all relevant parties (participants, personnel, and outcome assessors), strove for complete or near‐complete follow‐up, and had reporting transparency. </p> </li> <li> <p>5‐alpha reductase inhibitors (e.g. finasteride and dutasteride) and phosphodiesterase inhibitors (e.g. tadalafil) have been used to treat lower urinary tract infections. Future studies are needed to compare efficacy and adverse events between these drugs and naftopidil. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007360-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007360-sec-0022"></div> <div class="table" id="CD007360-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Naftopidil compared to tamsulosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Naftopidil compared to tamsulosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with lower urinary tract symptoms suggesting benign prostatic hyperplasia </p> <p><b>Setting:</b> likely outpatients </p> <p><b>Intervention:</b> naftopidil </p> <p><b>Comparator:</b> tamsulosin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with tamsulosin</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with naftopidil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urological symptom scores</b><br/> assessed with: IPSS<br/> Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/> Follow‐up: 4–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>965<br/> (12 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean urological symptom scores ranged from 9.2 to 10.7 (from 4 studies) and mean change of urological symptom scores ranged from –9.8 to –3.3 (from 8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.47 higher<br/> (0.09 lower to 1.04 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> assessed with: IPSS‐Quality of Life<br/> Scale from: 0 (best: delighted) to 6 (worst: terrible)<br/> Follow‐up: 4–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>878<br/> (11 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life ranged from 2.7 to 3.1 (from 3 studies) and mean change of quality of life ranged from –2.75 to –0.7 (from 8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.11 higher<br/> (0.09 lower to 0.30 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawals for any reason</b><br/> Follow‐up: 4–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>668<br/> (8 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.92</b><br/> (0.64 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 fewer per 1000<br/> (32 fewer to 31 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular adverse events</b><br/> Follow‐up: 4–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>824<br/> (9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.97</b><br/> (0.52 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 fewer per 1000<br/> (28 fewer to 47 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Sexual adverse events</b><br/> Follow‐up: 4–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>397<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.54</b><br/> (0.24 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 fewer per 1000<br/> (43 fewer to 13 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for study limitations: unclear or high risk of bias in one or more domains. </p> <p><sup>b</sup>Downgraded by one level for inconsistency: moderate‐to‐substantial heterogeneity. </p> <p><sup>c</sup>Downgraded by one level for imprecision: confidence interval crossed assumed threshold of clinically important difference. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007360-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Naftopidil compared to silodosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Naftopidil compared to silodosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with lower urinary tract symptoms suggesting benign prostatic hyperplasia </p> <p><b>Setting:</b> likely outpatients </p> <p><b>Intervention:</b> naftopidil </p> <p><b>Comparator:</b> silodosin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with silodosin</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with naftopidil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urological symptom scores</b><br/> Assessed with: IPSS<br/> Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/> Follow‐up: 6–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>652<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of urological symptom scores ranged from –8.6 to –4.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.04 higher<br/> (0.78 lower to 2.85 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> Assessed with: IPSS‐QoL<br/> Scale from: 0 (best: delighted) to 6 (worst: terrible)<br/> Follow‐up: 6–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>652<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of quality of life ranged from –2.0 to –0.98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.21 higher<br/> (0.23 lower to 0.66 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawals for any reason</b> </p> <p>Follow‐up: 8–12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>659<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.80</b><br/> (0.52 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 fewer per 1000<br/> (62 fewer to 30 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular adverse events</b> </p> <p>Follow‐up: 6–12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>808<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.98</b><br/> (0.39 to 2.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (15 fewer to 35 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Sexual adverse events</b> </p> <p>Follow‐up: 6–12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>348<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.15</b><br/> (0.06 to 0.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126 fewer per 1000<br/> (139 fewer to 86 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>IPSS‐QoL:</b> International Prostate Symptom Score – Quality of Life; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for study limitations: unclear or high risk of bias in one or more domains. </p> <p><sup>b</sup>Downgraded by one level for inconsistency: substantial heterogeneity. </p> <p><sup>c</sup>Downgraded by one level in imprecision: confidence interval crossed assumed threshold of clinically important difference. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007360-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Naftopidil compared to propiverine (anticholinergic) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Naftopidil compared to propiverine (anticholinergic) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with lower urinary tract symptoms suggesting benign prostatic hyperplasia </p> <p><b>Setting:</b> likely outpatients </p> <p><b>Intervention:</b> naftopidil </p> <p><b>Comparato</b> r<b>:</b> propiverine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with propiverine</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with naftopidil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urological symptom scores</b><br/> assessed with: IPSS<br/> Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/> Follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of urological symptom scores was –2.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.8 lower<br/> (6.99 lower to 1.39 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> assessed with: IPSS‐QoL<br/> Scale from: 0 (best: delighted) to 6 (worst: terrible)<br/> Follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of quality of life was –1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.1 higher<br/> (0.56 lower to 0.76 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawals for any reason</b><sup>c</sup><br/> follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular adverse events</b><sup>c</sup><br/> follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Sexual adverse events</b><sup>c</sup><br/> follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>IPSS‐QoL:</b> International Prostate Symptom Score – Quality of Life; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for study limitations: unclear risk of selection, performance, detection, and reporting bias. </p> <p><sup>b</sup>Downgraded by one level for imprecision: confidence interval crossed assumed threshold of clinically important difference of IPSS 3 and quality of life 0.5. </p> <p><sup>c</sup>Treatment withdrawal due to any reasons; cardiovascular adverse events; and sexual adverse events: no available data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007360-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Naftopidil compared to Eviprostat (phytotherapy) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Naftopidil compared to Eviprostat (phytotherapy) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with lower urinary tract symptoms suggesting benign prostatic hyperplasia </p> <p><b>Setting:</b> likely outpatients </p> <p><b>Intervention:</b> naftopidil </p> <p><b>Comparator:</b> Eviprostat </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Eviprostat</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with Naftopidil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urological symptom scores</b><br/> assessed with: IPSS<br/> Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/> Follow‐up: mean 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of urological symptom scores was 0.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 6.3 lower<br/> (9.46 lower to 3.14 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> assessed with: IPSS‐QoL<br/> Scale from: 0 (best: delighted) to 6 (worst: terrible)<br/> Follow‐up: mean 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of quality of life was 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.5 lower<br/> (2.36 lower to 0.64 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawals for any reason</b><br/> Follow‐up: mean 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR approximately 1 with wide CI</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawals due to adverse events</b><br/> Follow‐up: mean 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR approximately 1 with wide CI</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular adverse events</b><sup>c</sup><br/> Follow‐up: mean 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Sexual adverse events</b><sup>c</sup><br/> Follow‐up: mean 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>IPSS‐QoL:</b> International Prostate Symptom Score – Quality of Life; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for study limitations: unclear or high risk of bias in one or more domains. </p> <p><sup>b</sup>Downgraded by two level for imprecision: RR approximately 1 with wide confidence interval and no events. </p> <p><sup>c</sup>Cardiovascular adverse events and sexual adverse events: no available data. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007360-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007360-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007360-sec-0149">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD007360-sec-0023"></div> <section id="CD007360-sec-0024"> <h3 class="title" id="CD007360-sec-0024">Description of the condition</h3> <p>Benign prostatic hyperplasia (BPH) is a common condition in elderly men and refers to the non‐malignant proliferation of smooth muscle, connective tissue, and glandular epithelium within the prostate, which may result in prostatic urethra obstruction (<a href="./references#CD007360-bbs2-0085" title="RoehrbornCG . Pathology of benign prostatic hyperplasia. International Journal of Impotence Research2008;20 Suppl 3:S11‐8. ">Roehrborn 2008</a>). The exact aetiology of BPH is currently unknown. Several suggestive risk factors are ageing, familial history, changes in hormonal levels, elevated markers of inflammation, and metabolic syndrome (<a href="./references#CD007360-bbs2-0086" title="RussoGI , CastelliT , UrzìD , PriviteraS , LaVigneraS , CondorelliRA , et al. Emerging links between non‐neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: a systematic review. International Journal of Urology2015;22(11):982‐90. ">Russo 2015</a>). Cellular proliferations in the periurethral and transition zones lead to the formation of nodular adenomas, potentially distorting the bladder neck and prostatic urethra. Such occurrence of anatomical changes and prostatic obstruction result in lower urinary tract symptoms (LUTS). There are two categories of LUTS; voiding symptoms (which include hesitancy, weak stream, urinary retention, postmicturition dribble, straining, and incomplete emptying) and storage symptoms (such as frequency, urgency, and nocturia) (<a href="./references#CD007360-bbs2-0078" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. ">McVary 2011</a>). </p> <p>Generally, greater severity of LUTS relates to more detrimental quality of life (QoL) and a greater desire for treatment (<a href="./references#CD007360-bbs2-0035" title="AgarwalA , EryuzluLN , CartwrightR , ThorlundK , TammelaTL , GuyattGH , et al. What is the most bothersome lower urinary tract symptom? Individual‐ and population‐level perspectives for both men and women. European Urology2014;65(6):1211‐7. ">Agarwal 2014</a>). Patient self‐report using a validated urinary symptom scale, such as International Prostate Symptom Score (IPSS), is used to evaluate symptom severity and QoL; this is an integral part of epidemiological and treatment studies (<a href="./references#CD007360-bbs2-0039" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesK , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154(5):1770‐4. ">Barry 1995</a>). Increasing IPSS symptom severity (LUTS severity) is also associated with patient perception of bladder condition, which is regarded as men's overall distress and increased healthcare seeking (<a href="./references#CD007360-bbs2-0043" title="ChappleC , Castro‐DiazD , ChuangYC , LeeKS , LiaoL , LiuSP , et al. Prevalence of lower urinary tract symptoms in China, Taiwan, and South Korea: results from a cross‐sectional, population‐based study. Advances in Therapy2017;34(8):1953‐65. ">Chapple 2017</a>). In this Cochrane Review, we used the term BPH as prostatic enlargement with LUTS through which to define the disease condition and potential need for intervention. </p> <p>Many of the complications of progressive BPH are rare, even though untreated; however, bladder stones, bladder decompensation, urinary tract infections, haematuria, and azotaemia can occur, requiring medical or surgical intervention. BPH has also been related with other medical conditions, reduced QoL, and increased annual healthcare costs (<a href="./references#CD007360-bbs2-0068" title="KaplanAL , AgarwalN , SetlurNP , TanHJ , NiedzwieckiD , McLaughlinN , et al. Measuring the cost of care in benign prostatic hyperplasia using time‐driven activity‐based costing (TDABC). Healthcare2015;3(1):43‐8. ">Kaplan 2015</a>; <a href="./references#CD007360-bbs2-0070" title="KozminskiMA , WeiJT , NelsonJ , KentDM . Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH). BJU International2015;115(2):308‐16. ">Kozminski 2015</a>; <a href="./references#CD007360-bbs2-0075" title="MartinS , LangeK , HarenMT , TaylorAW , WittertG . Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. Journal of Urology2014;191(1):130‐7. ">Martin 2014</a>). </p> <section id="CD007360-sec-0025"> <h4 class="title">Diagnosis</h4> <p>The diagnosis of BPH is based on followed clinical features; a prostate enlargement, bothersome LUTS, and no other identified causes for the urinary problems. The initial evaluation of BPH includes medical history, symptom score questionnaires (IPSS), physical examination including a digital rectal examination, urinalysis, prostate‐specific antigen (PSA) blood test, and frequency volume chart (<a href="./references#CD007360-bbs2-0050" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 17 August 2017). ">EAU 2017</a>; <a href="./references#CD007360-bbs2-0078" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. ">McVary 2011</a>). The IPSS questionnaire is composed of three domains related to storage symptoms (frequency, urgency, and nocturia); four domains related to voiding symptoms (hesitancy, weak stream, intermittence, and incomplete emptying); and one QoL domain (<a href="./references#CD007360-bbs2-0037" title="AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. Journal of Urology2003;170(2 Pt 1):530‐47. ">AUA Practice Guidelines Committee 2003</a>; <a href="./references#CD007360-bbs2-0038" title="BarryMJ , FowlerFJJr , O'LearyMP , BruskewitzRC , HoltgreweHL , MebustWK , et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. Journal of Urology1992;148(5):1549‐57. ">Barry 1992</a>). Seven symptom domains use a 6‐point scale ranging from 0 (none) to 5 (five or more) (<a href="./references#CD007360-bbs2-0038" title="BarryMJ , FowlerFJJr , O'LearyMP , BruskewitzRC , HoltgreweHL , MebustWK , et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. Journal of Urology1992;148(5):1549‐57. ">Barry 1992</a>). The QoL domain is assigned a score from 1 to 6 (ordinal and range from 0 to 6: 0 = delighted, 1 = pleased, 2 = mostly satisfied, 3 = mixed, 4 = mostly dissatisfied, 5 = unhappy, 6 = terrible) (<a href="./references#CD007360-bbs2-0037" title="AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. Journal of Urology2003;170(2 Pt 1):530‐47. ">AUA Practice Guidelines Committee 2003</a>; <a href="./references#CD007360-bbs2-0038" title="BarryMJ , FowlerFJJr , O'LearyMP , BruskewitzRC , HoltgreweHL , MebustWK , et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. Journal of Urology1992;148(5):1549‐57. ">Barry 1992</a>). Another validated symptom score questionnaire, BPH Impact Index (BII), was developed to assess the effect of LUTS/BPH on men's health. The BII questionnaire is composed of four items: physical discomfort (0 = none, 1 = only a little, 2 = some, 3 = a lot); worry item (0 = none, 1 = only a little, 2 = some, 3 = a lot); bother item (0 = not at all bothersome, 1 = bothers me a little, 2 = bothers me some, 3 = bothers me a lot); the interference with usual activities item (0 = none of the time, 1 = a little of the time, 2 = some of the time, 3 = most of the time, 4 = all of the time) (<a href="./references#CD007360-bbs2-0039" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesK , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154(5):1770‐4. ">Barry 1995</a>). Symptom score questionnaires should be delivered to objectively identify and quantify LUTS. These are also sensitive to symptom changes and treatment monitoring (<a href="./references#CD007360-bbs2-0050" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 17 August 2017). ">EAU 2017</a>; <a href="./references#CD007360-bbs2-0078" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. ">McVary 2011</a>). A digital rectal examination is an important examination and may help to determine the coexistence of prostate cancer. Urinalysis is useful for differential diagnosis to urinary tract infection. Together with a digital rectal examination, a PSA test increases the detection rate of prostate cancer, but would be performed if life expectancy is greater than 10 years and if a diagnosis of prostate cancer would modify the management approach (<a href="./references#CD007360-bbs2-0050" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 17 August 2017). ">EAU 2017</a>; <a href="./references#CD007360-bbs2-0078" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. ">McVary 2011</a>). Measurement of urinary flow rates and residual urine are helpful in diagnostic evaluation and treatment response (<a href="./references#CD007360-bbs2-0050" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 17 August 2017). ">EAU 2017</a>; <a href="./references#CD007360-bbs2-0078" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. ">McVary 2011</a>). A decreased urinary flow rate and large residual urine are risk factors of symptom aggravation (<a href="./references#CD007360-bbs2-0046" title="CrawfordED , WilsonSS , McConnellJD , SlawinKM , LieberMC , SmithJA , et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. Journal of Urology2006;175(4):1422‐6; discussion 1426‐7. ">Crawford 2006</a>). Other tests include radiological imaging, pressure flow study, and urethrocystoscopy are not recommended as a routine diagnostic procedure except in selective conditions which affect treatment decisions (<a href="./references#CD007360-bbs2-0078" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. ">McVary 2011</a>). </p> </section> <section id="CD007360-sec-0026"> <h4 class="title">Treatment</h4> <p>The role of treatment for any disease process depends on the magnitude of the clinical effect and the incidence and severity of treatment‐related morbidity. In addition, the degree of bother resulting from BPH is the main factor for receiving a treatment. A significant proportion of men with LUTS will not choose medical or surgical intervention because the symptoms are not bothersome. These men are suitable for watchful waiting (<a href="./references#CD007360-bbs2-0081" title="NettoNRJr , deLimaML , NettoMR , D'AnconaCA . Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology1999;53(2):314‐6. ">Netto 1999</a>) and lifestyle modification (<a href="./references#CD007360-bbs2-0093" title="YapTL , BrownC , CromwellDA , Van derMeulenJ , EmbertonM . The impact of self‐management of lower urinary tract symptoms on frequency‐volume chart measures. BJU International2009;104(8):1104‐8. ">Yap 2009</a>). Men who complain of moderate‐to‐severe bother with symptoms are likely to benefit from medical (alpha‐blockers (ABs), 5‐alpha reductase inhibitors (5‐ARIs), and combination therapy) or surgical treatment (<a href="./references#CD007360-bbs2-0050" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 17 August 2017). ">EAU 2017</a>; <a href="./references#CD007360-bbs2-0078" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. ">McVary 2011</a>). ABs reduce smooth muscle tone in the prostate and bladder neck with/without 5‐ARIs, which reduces prostate volume by inducing epithelial atrophy. They are an established treatment in LUTS/BPH and have been widely used as first‐line therapy since the late 1990s (<a href="./references#CD007360-bbs2-0077" title="McConnellJD , RoehrbornCG , BautistaOM , AndrioleGLJr , DixonCM , KusekJW , et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long‐term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine2003;349(25):2387‐98. ">McConnell 2003</a>; <a href="./references#CD007360-bbs2-0080" title="MilaniS , DjavanB . Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha‐adrenoceptor antagonists. BJU International2005;95 Suppl 4:29‐36. ">Milani 2005</a>; <a href="./references#CD007360-bbs2-0094" title="YooTK , ChoHJ . Benign prostatic hyperplasia: from bench to clinic. Korean Journal of Urology2012;53(3):139‐48. ">Yoo 2012</a>). In particular, ABs that can decrease smooth muscle tone in the prostate and bladder neck have been considered as fundamental pharmacotherapy for men with BPH (<a href="./references#CD007360-bbs2-0044" title="CornuJN , CussenotO , HaabF , LukacsB . A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. European Urology2010;58(3):450‐6. ">Cornu 2010</a>; <a href="./references#CD007360-bbs2-0080" title="MilaniS , DjavanB . Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha‐adrenoceptor antagonists. BJU International2005;95 Suppl 4:29‐36. ">Milani 2005</a>; <a href="./references#CD007360-bbs2-0094" title="YooTK , ChoHJ . Benign prostatic hyperplasia: from bench to clinic. Korean Journal of Urology2012;53(3):139‐48. ">Yoo 2012</a>). Prior systematic reviews have shown that ABs can typically reduce IPSS by 20% to 50% and increase Q<sub>max</sub> by 15% to 45% (<a href="./references#CD007360-bbs2-0074" title="MacDonaldR , WiltTJ . Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology2005;66(4):780‐8. ">MacDonald 2005</a>; <a href="./references#CD007360-bbs2-0092" title="WiltTJ , MacDonaldR . Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clinical Interventions in Aging2006;1(4):389‐401. ">Wilt 2006</a>). ABs are the most commonly prescribed category of drug for LUTS/BPH, accounting for about 70% of all medications prescribed in 2008 (<a href="./references#CD007360-bbs2-0044" title="CornuJN , CussenotO , HaabF , LukacsB . A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. European Urology2010;58(3):450‐6. ">Cornu 2010</a>). Adverse effects of ABs include postural hypotension, dizziness, headache, asthenia, syncope, peripheral oedema, and retrograde ejaculation, which cause approximately 4% to 10% of men to withdraw from AB treatment (<a href="./references#CD007360-bbs2-0049" title="DjavanB , MarbergerM . A meta‐analysis on the efficacy and tolerability of alpha1‐adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. European Urology1999;36(1):1‐13. ">Djavan 1999</a>; <a href="./references#CD007360-bbs2-0054" title="GacciM , FicarraV , SebastianelliA , CoronaG , SerniS , ShariatSF , et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta‐analysis. Journal of Sexual Medicine2014;11(6):1554‐66. ">Gacci 2014</a>; <a href="./references#CD007360-bbs2-0074" title="MacDonaldR , WiltTJ . Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology2005;66(4):780‐8. ">MacDonald 2005</a>; <a href="./references#CD007360-bbs2-0087" title="SchulmanCC . Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology2003;62(3 Suppl 1):24‐33. ">Schulman 2003</a>; <a href="./references#CD007360-bbs2-0092" title="WiltTJ , MacDonaldR . Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clinical Interventions in Aging2006;1(4):389‐401. ">Wilt 2006</a>). Other medical therapies, such as anticholinergics and desmopressin, have been used with ABs, depending on the main symptoms (<a href="./references#CD007360-bbs2-0041" title="BrasureM , MacDonaldR , DahmP , OlsonCM , NelsonVA , FinkHA , et al. AHRQ comparative effectiveness reviews. Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: a Review. Rockville (MD): Agency for Healthcare Research and Quality (US), 2016:6. ">Brasure 2016</a>; <a href="./references#CD007360-bbs2-0047" title="DahmP , BrasureM , MacDonaldR , OlsonCM , NelsonVA , FinkHA . Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta‐analysis. European Urology2017;71(4):570‐81. ">Dahm 2017</a>; <a href="./references#CD007360-bbs2-0050" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 17 August 2017). ">EAU 2017</a>). Also, a phosphodiesterase type 5 inhibitor, tadalafil (5 mg once daily), has been licensed for the treatment of male LUTS, and various plant extracts (e.g., Cucurbita pepo; pumpkin seeds, Hypoxis rooperi; South African star grass, Pygeum africanum; bark of the African plum tree, Secale cereale; rye pollen, Serenoa repens; saw palmetto and Urtica dioica; roots of the stinging nettle) have been proposed for the treatment of male LUTS (<a href="./references#CD007360-bbs2-0050" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 17 August 2017). ">EAU 2017</a>; <a href="./references#CD007360-bbs2-0069" title="KeehnA , TaylorJ , LoweFC . Phytotherapy for benign prostatic hyperplasia. Current Urology Reports2016;17(7):53. ">Keehn 2016</a>; <a href="./references#CD007360-bbs2-0082" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>). Surgical treatment was considered in cases of symptoms refractory to medical treatment or traditional absolute indications (e.g. acute urinary retention (AUR), recurrent urinary tract infection, bladder stones or diverticula, haematuria, or renal insufficiency) (<a href="./references#CD007360-bbs2-0050" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 17 August 2017). ">EAU 2017</a>; <a href="./references#CD007360-bbs2-0078" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. ">McVary 2011</a>). </p> </section> </section> <section id="CD007360-sec-0027"> <h3 class="title" id="CD007360-sec-0027">Description of the intervention</h3> <p>Naftopidil is selective for the A1d adrenergic receptor with a three‐ to 17‐fold higher affinity than for the A1a and A1b adrenergic receptor subtypes based on in vitro studies and was approved in Japan in 1998 (<a href="./references#CD007360-bbs2-0091" title="TakeiR , IkegakiI , ShibataK , TsujimotoG , AsanoT . Naftopidil, a novel alpha1‐adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1‐adrenoceptors. Japanese Journal of Pharmacology1999;79(4):447‐54. ">Takei 1999</a>). Naftopidil should be more effective for storage symptoms measured by IPSS due to its selectivity for the bladder via the A1d receptor subtype. Initial randomised controlled trials (RCTs) found no significant difference in IPSS and QoL (QoL) compared with tamsulosin (<a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>). Along with these studies, several RCTs also reported that naftopidil was as effective as tamsulosin (<a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>). There were no significant differences in the incidence of adverse events between the naftopidil and tamsulosin groups (<a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>). </p> </section> <section id="CD007360-sec-0028"> <h3 class="title" id="CD007360-sec-0028">How the intervention might work</h3> <p>The A1a adrenergic receptors are a class of G protein‐coupled receptors that consist of three homologous subtypes, including A1a, A1b, and A1d receptors. The A1a receptor subtype predominates in the human prostate, bladder neck, and urethra (<a href="./references#CD007360-bbs2-0072" title="LeporH . Alpha‐blockers for the treatment of benign prostatic hyperplasia. Urologic Clinics of North America2016;43(3):311‐23. ">Lepor 2016</a>; <a href="./references#CD007360-bbs2-0079" title="MichelM , SchafersR , GoepelM . Alpha‐blockers and lower urinary tract function: more than smooth muscle relaxation?. BJU international2000;86 Suppl 2:23‐8; discussion 28‐30. ">Michel 2000</a>; <a href="./references#CD007360-bbs2-0088" title="SchwinnDA , RoehrbornCG . Alpha1‐adrenoceptor subtypes and lower urinary tract symptoms. International Journal of Urology2008;15(3):193‐9. ">Schwinn 2008</a>). A1b receptor subtypes are mainly expressed in the peripheral vasculature and are important in the regulation of blood pressure. The A1d receptor is expressed in the detrusor muscle of the bladder and the sacral region of the spinal cord (<a href="./references#CD007360-bbs2-0072" title="LeporH . Alpha‐blockers for the treatment of benign prostatic hyperplasia. Urologic Clinics of North America2016;43(3):311‐23. ">Lepor 2016</a>; <a href="./references#CD007360-bbs2-0079" title="MichelM , SchafersR , GoepelM . Alpha‐blockers and lower urinary tract function: more than smooth muscle relaxation?. BJU international2000;86 Suppl 2:23‐8; discussion 28‐30. ">Michel 2000</a>; <a href="./references#CD007360-bbs2-0088" title="SchwinnDA , RoehrbornCG . Alpha1‐adrenoceptor subtypes and lower urinary tract symptoms. International Journal of Urology2008;15(3):193‐9. ">Schwinn 2008</a>). Naftopidil, which shows greater selectivity for A1d over the A1a subtype, was reported to be more effective in improving storage symptoms than tamsulosin with greater selectivity for the A1a over the A1d subtype (<a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>). In addition, experimental studies have shown that A1d‐ARs greatly outnumber A1a‐ARs in the bladder and are upregulated in bladder outlet obstruction (<a href="./references#CD007360-bbs2-0059" title="HampelC , DolberPC , SmithMP , SavicSL , Th roffJW , ThorKB , et al. Modulation of bladder alpha1‐adrenergic receptor subtype expression by bladder outlet obstruction. Journal of Urology2002;167(3):1513‐21. ">Hampel 2002</a>). Therefore, naftopidil may have a therapeutic effect for BPH improving obstruction symptoms and storage symptoms with similar vascular adverse effects, such as dizziness, orthostatic hypotension, which were commonly observed in other ABs. </p> </section> <section id="CD007360-sec-0029"> <h3 class="title" id="CD007360-sec-0029">Why it is important to do this review</h3> <p>Naftopidil is not available in Western countries because of non‐Asian randomised clinical trials and lack of placebo‐controlled trials. Therefore, the potential advantages or harms of naftopidil (selective A1d‐AR blockade) in the treatment of LUTS cannot be assessed until a drug with appropriate subtype selectivity becomes available for clinical evaluation (<a href="./references#CD007360-bbs2-0036" title="AnderssonKE . LUTS treatment: future treatment options. Neurourology and Urodynamics2007;26(6 Suppl):934‐47. ">Andersson 2007</a>). One previous Cochrane Review for naftopidil for the treatment of LUTSs compatible with BPH based on RCTs demonstrated that IPSS and QoL improvement were similar to low‐dose tamsulosin (0.2 mg/day) but more improved compared to phytotherapy (Eviprostat) and adverse events due to naftopidil were few and usually mild (<a href="./references#CD007360-bbs2-0096" title="GarimellaPS , FinkHA , MacdonaldR , WiltTJ . Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007360.pub2] ">Garimella 2009</a>). After publication of the <a href="./references#CD007360-bbs2-0096" title="GarimellaPS , FinkHA , MacdonaldR , WiltTJ . Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007360.pub2] ">Garimella 2009</a> review, Cochrane introduced more rigorous methodology, which included assessment of risk of bias and production of 'Summary of findings' tables (the GRADE approach). Furthermore, results of several randomised trials for naftopidil have been reported since the <a href="./references#CD007360-bbs2-0096" title="GarimellaPS , FinkHA , MacdonaldR , WiltTJ . Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007360.pub2] ">Garimella 2009</a> review. Therefore, the previous review must be considered outdated. This is an update of the Cochrane Review first published in 2009 (<a href="./references#CD007360-bbs2-0096" title="GarimellaPS , FinkHA , MacdonaldR , WiltTJ . Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007360.pub2] ">Garimella 2009</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007360-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007360-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007360-sec-0156">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007360-sec-0030"></div> <p>To evaluate the effects of naftopidil, for the treatment of LUTS associated with BPH.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007360-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007360-sec-0031">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007360-sec-0157">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007360-sec-0031"></div> <section id="CD007360-sec-0032"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007360-sec-0033"> <h4 class="title">Types of studies</h4> <p>We included parallel, RCTs regardless of their publication status or language of publication. We also included cross‐over designs. </p> </section> <section id="CD007360-sec-0034"> <h4 class="title">Types of participants</h4> <p>We included adult men (aged 40 years and over) with LUTS/BPH. The age limitation was based on the observation that the prevalence of BPH increases in middle‐aged and older men (<a href="./references#CD007360-bbs2-0040" title="BarryMJ , FowlerFJJr , BinL , PittsJC3rd , HarrisCJ , MulleyAGJr . The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. Journal of Urology1997;157(1):10‐4; discussion 14‐5. ">Barry 1997</a>; <a href="./references#CD007360-bbs2-0051" title="EganKB . The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clinics of North America2016;43(3):289‐97. ">Egan 2016</a>), and is infrequent in younger men. </p> <p>We excluded trials of men with a known neurogenic bladder due to spinal cord injury, multiple sclerosis, or central nervous system disease, and men who had been previously treated with surgery for BPH. We included studies that their data were available separately for analysis rather than using the whole population. </p> </section> <section id="CD007360-sec-0035"> <h4 class="title">Types of interventions</h4> <p>We investigated the following comparisons of experimental intervention versus comparator intervention. Concomitant interventions were allowed but had to be the same in the experimental and comparator groups to establish fair comparisons. </p> <section id="CD007360-sec-0036"> <h5 class="title">Experimental interventions</h5> <p> <ul id="CD007360-list-0001"> <li> <p>Naftopidil.</p> </li> <li> <p>Naftopidil plus any 5‐ARIs (if available).</p> </li> </ul> </p> <p>In the past, naftopidil 25 mg/day was initially administered, increasing to 50 mg/day to 75 mg/day over an interval of one to two weeks if needed (<a href="./references#CD007360-bbs2-0032" title="YokoyamaT , KumonH , NasuY , TakamotoH , WatanabeT . Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. International Journal of Urology2006;13(7):932‐8. ">Yokoyama 2006</a>). Currently, naftopidil 50 mg/day is the initial clinical recommended dosage (<a href="./references#CD007360-bbs2-0076" title="MasumoriN . Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia. Therapeutics and Clinical Risk Management2011;7:227‐38. ">Masumori 2011</a>). One study reported that naftopidil 75 mg/day was also useful for Korean men with BPH to improve total IPSS and OABSS (<a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>). We included trials with doses of naftopidil at 25 mg/day, 50 mg/day, and 75 mg/day. </p> </section> <section id="CD007360-sec-0037"> <h5 class="title">Comparator interventions</h5> <p> <ul id="CD007360-list-0002"> <li> <p>Placebo.</p> </li> <li> <p>Other ABs.</p> </li> <li> <p>Other ABs plus any 5‐ARIs (if available).</p> </li> <li> <p>Anticholinergics.</p> </li> <li> <p>Phytotherapy. (e.g. plant extracts)</p> </li> </ul> </p> </section> <section id="CD007360-sec-0038"> <h5 class="title">Comparisons</h5> <p> <ul id="CD007360-list-0003"> <li> <p>Naftopidil versus placebo.</p> </li> <li> <p>Naftopidil versus other ABs.</p> </li> <li> <p>Naftopidil plus any 5‐ARIs (If available) versus other ABs plus any 5‐ARIs (if available).</p> </li> <li> <p>Naftopidil versus anticholinergics.</p> </li> <li> <p>Naftopidil versus phytotherapy.</p> </li> </ul> </p> </section> </section> <section id="CD007360-sec-0039"> <h4 class="title">Types of outcome measures</h4> <section id="CD007360-sec-0040"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007360-list-0004"> <li> <p>Urological symptom scores.</p> </li> <li> <p>QoL.</p> </li> <li> <p>Treatment withdrawals for any reason.</p> </li> </ul> </p> </section> <section id="CD007360-sec-0041"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007360-list-0005"> <li> <p>Treatment withdrawals due to adverse events.</p> </li> <li> <p>AUR.</p> </li> <li> <p>Surgical intervention for LUTS/BPH.</p> </li> <li> <p>Cardiovascular adverse events.</p> </li> <li> <p>Sexual adverse events.</p> </li> </ul> </p> <section id="CD007360-sec-0042"> <h6 class="title">Method and timing of outcome measurement</h6> <p> <ul id="CD007360-list-0006"> <li> <p>Urological symptom scores: final value or change from baseline assessed with a validated scale (such as IPSS). </p> </li> <li> <p>QoL: final value or change from baseline assessed with a validated scale (such as IPSS‐Quality of Life or BII scores). </p> </li> <li> <p>Treatment withdrawals for any reason: defined as treatment discontinuation for any cause at any time after participants were randomised to intervention/comparator groups. </p> </li> <li> <p>Treatment withdrawals due to adverse events: defined as treatment discontinuation due to adverse events at any time after participants were randomised to intervention/comparator groups. </p> </li> <li> <p>AUR: events requiring catheterisation.</p> </li> <li> <p>Surgical intervention for LUTS/BPH: events requiring other surgical treatment modalities (e.g. transurethral resection of the prostate (TURP)). </p> </li> <li> <p>Cardiovascular adverse events: such as dizziness, headache, orthostatic hypotension, and syncope. </p> </li> <li> <p>Sexual adverse events: such as retrograde ejaculation, anejaculation, and decreased libido. </p> </li> </ul> </p> <p>We used clinically important differences for the outcomes when available to judge the magnitude of the effect in the context of rating the certainty of the evidence in the ''Summary of finding' tables (<a href="./references#CD007360-bbs2-0065" title="JaeschkeR , SingerJ , GuyattGH . Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials1989;10(4):407‐15. ">Jaeschke 1989</a>; <a href="./references#CD007360-bbs2-0066" title="JohnstonBC , PatrickDL , ThorlundK , BusseJW , daCostaBR , SchünemannHJ , et al. Patient‐reported outcomes in meta‐analyses ‐ part 2: methods for improving interpretability for decision‐makers. Health and Quality of Life Outcomes2013;11:211. ">Johnston 2013</a>). When the mean difference (MD) or risk ratio (RR) was equal to or larger than the minimal clinically important difference (MCID), we assumed that many participants may have gained a clinically meaningful improvement from treatment. </p> <p>We considered MCID in the IPSS to be 3 point, BII score to be 0.5 points, and IPSS‐Quality of Life to be 0.5 points (<a href="./references#CD007360-bbs2-0039" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesK , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154(5):1770‐4. ">Barry 1995</a>; <a href="./references#CD007360-bbs2-0041" title="BrasureM , MacDonaldR , DahmP , OlsonCM , NelsonVA , FinkHA , et al. AHRQ comparative effectiveness reviews. Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: a Review. Rockville (MD): Agency for Healthcare Research and Quality (US), 2016:6. ">Brasure 2016</a>; <a href="./references#CD007360-bbs2-0083" title="ReesJ . Patients not P values. BJU International2015;115(5):678‐9. ">Rees 2015</a>). We did not establish thresholds for treatment withdrawals due to adverse events, AUR, surgical intervention for LUTS/BPH, cardiovascular adverse events, and sexual adverse events. We considered the clinically important differences of all listed outcomes above as a RR increase of at least 25% (<a href="./references#CD007360-bbs2-0057" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. ">Guyatt 2011a</a>). We considered outcomes measured up to and including 12 months after randomisation as short term, and later than 12 months as long term. </p> <p> <ul id="CD007360-list-0007"> <li> <p>Up to 12 months (short term).</p> </li> <li> <p>More than 12 months (long term).</p> </li> </ul> </p> </section> <section id="CD007360-sec-0043"> <h6 class="title">Main outcomes for 'Summary of findings' tables</h6> <p>We presented 'Summary of findings' tables reporting the following outcomes listed according to the perceived priority to men with LUTS/BPH. </p> <p> <ul id="CD007360-list-0008"> <li> <p>Urological symptom scores.</p> </li> <li> <p>QoL.</p> </li> <li> <p>Treatment withdrawals for any reason.</p> </li> <li> <p>Cardiovascular adverse events.</p> </li> <li> <p>Sexual adverse events.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD007360-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>We performed a comprehensive search with no restrictions on the language of publication or publication status. We updated searches within three months prior to the anticipated publication of the review. </p> <section id="CD007360-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We initially searched the following sources from inception of each database to 8 October 2017. The date of last search of all databases was 31 May 2018. See <a href="./appendices#CD007360-sec-0135">Appendix 1</a>. </p> <p> <ul id="CD007360-list-0009"> <li> <p>Cochrane Library (via Wiley):</p> <ul id="CD007360-list-0010"> <li> <p>Cochrane Database of Systematic Reviews;</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>Database of Abstracts of Reviews of Effects;</p> </li> <li> <p>Health Technology Assessment Database.</p> </li> </ul> </li> <li> <p>MEDLINE (PubMed).</p> </li> <li> <p>Embase (Ovid).</p> </li> <li> <p>Scopus.</p> </li> <li> <p>LILAC (<a href="http://bvsalud.org/en" target="_blank">bvsalud.org/en</a>). </p> </li> <li> <p>Web of Science.</p> </li> </ul> </p> <p>We also searched the following trials registers on 8 October 2017 and 31 May 2018.</p> <p> <ul id="CD007360-list-0011"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform search portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> <li> <p>Grey Literature Report (<a href="http://www.opengrey.eu" target="_blank">www.opengrey.eu</a>). </p> </li> </ul> </p> </section> <section id="CD007360-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of retrieved included trials, reviews, meta‐analyses, and health technology assessment reports to identify other potentially eligible trials or ancillary publications. We contacted study authors of included trials to identify any further studies that we might have missed. We contacted drug/device manufacturers for ongoing or unpublished trials. We searched for unpublished studies by handsearching the abstract proceedings of the annual meetings of the American Urological Association, European Association of Urology, and International Continence Society for 2015 to 2017 and then updated the search in 2018. </p> </section> </section> <section id="CD007360-sec-0047"> <h3 class="title" id="CD007360-sec-0047">Data collection and analysis</h3> <section id="CD007360-sec-0048"> <h4 class="title">Selection of studies</h4> <p>We used reference management software to identify and remove potential duplicate records (<a href="./references#CD007360-bbs2-0052" title="Clarivate Analytics. EndNote. Version 7.5. Philadelphia (PA): Clarivate Analytics, 2016. ">EndNote</a>). Two review authors (ECH, JHJ) independently scanned the abstract, title, or both, of remaining records retrieved to determine which studies should be assessed further. Two review authors (ECH, JHJ) investigated all potentially relevant records as full text; mapped records to studies; and classified studies as included studies, excluded studies, studies awaiting classification, or ongoing studies, in accordance with the criteria for each provided in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007360-bbs2-0062" title="HigginsJP , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). We used <a href="./references#CD007360-bbs2-0045" title="Veritas Health Innovation. Covidence. Version accessed 17 November 2017. Melbourne, Australia: Veritas Health Innovation, 2013. ">Covidence</a> for title/abstract, and full‐text screening. We resolved any discrepancies through consensus or recourse to a third review author (PD). If resolution of a disagreement was not possible, we designated the study as 'awaiting classification' and contacted study authors for clarification. We documented reasons for exclusion of studies that may have reasonably been expected to be included in the review in the <a href="./references#CD007360-sec-0147" title="">Characteristics of excluded studies</a> table. We presented an adapted PRISMA flow diagram showing the process of study selection (<a href="./references#CD007360-bbs2-0073" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. ">Liberati 2009</a>). </p> </section> <section id="CD007360-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>We developed a dedicated data abstraction form that we pilot tested ahead of time. For studies that fulfilled the inclusion criteria, two review authors (ECH, JHJ) independently abstracted the following information, which we provided in the <a href="./references#CD007360-sec-0146" title="">Characteristics of included studies</a> table. </p> <p> <ul id="CD007360-list-0012"> <li> <p>Study design.</p> </li> <li> <p>Study dates.</p> </li> <li> <p>Study settings and country.</p> </li> <li> <p>Participant inclusion and exclusion criteria (e.g. age, baseline IPSS).</p> </li> <li> <p>Participant details, baseline demographics (e.g. age, ethnic background, IPSS).</p> </li> <li> <p>Number of participants by study and by study arm.</p> </li> <li> <p>Details of relevant experimental and comparator interventions such as frequency (e.g. once daily or twice daily) and treatment duration (in weeks or months). </p> </li> <li> <p>Definitions of relevant outcomes and method (e.g. type of instrument such as IPSS) and timing of outcome measurement (e.g. in weeks or months) as well as any relevant subgroups (e.g. based on age). </p> </li> <li> <p>Study funding sources.</p> </li> <li> <p>Declarations of interest by primary investigators.</p> </li> </ul> </p> <p>We extracted outcome data relevant to this Cochrane Review as needed for calculation of summary statistics and measures of variance. For dichotomous outcomes, we obtained numbers of events and totals for completion of a 2 × 2 table, as well as summary statistics with corresponding measures of variance. For continuous outcomes, we obtained means and standard deviations or data necessary to calculate this information. We attempted to contact authors of included and excluded studies to obtain key missing data as needed. </p> <section id="CD007360-sec-0050"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents, or multiple reports of a primary study, we maximised yield of information by mapping all publications to unique studies and collating all available data. We used the most complete data‐set aggregated across all known publications. In case of doubt, we gave priority to the publication reporting the longest follow‐up associated with our primary or secondary outcomes. </p> </section> </section> <section id="CD007360-sec-0051"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SG, JHJ) independently assessed the risk of bias of each included study. We resolved disagreements by consensus, or by consultation with a third review author (PD). </p> <p>We assessed risk of bias using Cochrane's 'Risk of bias' assessment tool for the following domains (<a href="./references#CD007360-bbs2-0063" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from handbook.cochrane.org. ">Higgins 2011b</a>). </p> <p> <ul id="CD007360-list-0013"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Other sources of bias (e.g. run‐in period, absence of washout period in cross‐over trial, baseline imbalance). </p> </li> </ul> </p> <p>We judged risk of bias domains as 'low risk,' 'high risk,' or 'unclear risk' and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007360-bbs2-0063" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from handbook.cochrane.org. ">Higgins 2011b</a>). We presented a 'Risk of bias' summary figure to illustrate these findings. For selection bias (random sequence generation and allocation concealment), we evaluated risk of bias at a trial level. For performance bias (blinding of participants and personnel), we considered that all outcomes were susceptible to performance bias and assessed in one group. For detection bias (blinding of outcome assessment), we grouped outcomes as susceptible to detection bias (subjective) or not susceptible to detection bias (objective) outcomes. We defined the following outcomes as susceptible to bias (subjective outcomes). </p> <p> <ul id="CD007360-list-0014"> <li> <p>Urological symptom scores.</p> </li> <li> <p>QoL.</p> </li> <li> <p>Treatment withdrawals for any reason.</p> </li> <li> <p>Treatment withdrawals due to adverse events.</p> </li> <li> <p>Cardiovascular adverse events.</p> </li> <li> <p>Sexual adverse events.</p> </li> </ul> </p> <p>We defined the following outcomes as not susceptible to bias (objective outcomes).</p> <p> <ul id="CD007360-list-0015"> <li> <p>AUR.</p> </li> <li> <p>Surgical intervention for LUTS/BPH.</p> </li> </ul> </p> <p>We initially assessed attrition bias (incomplete outcome data) on a per‐outcome basis but created groups of outcomes based on similar reporting characteristic. </p> <p>For reporting bias (selective reporting), we evaluated risk of bias on a trial level.</p> <p>We further summarised the risk of bias across domains for each outcome in each included study, as well as across studies and domains for each outcome, in accordance with the approach for summary assessments of the risk of bias presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007360-bbs2-0063" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from handbook.cochrane.org. ">Higgins 2011b</a>). </p> </section> <section id="CD007360-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous data as RRs with 95% confidence intervals (CIs). We expressed continuous data as MDs with 95% CIs unless different studies used different measures to assess the same outcome, in which case we expressed data as standardised MDs with 95% CIs. </p> </section> <section id="CD007360-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. For cross‐over trials or trials with more than two intervention groups, we planned to incorporate these study designs in meta‐analyses in accordance with guidance provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007360-bbs2-0064" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). </p> </section> <section id="CD007360-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>We obtained missing data from study authors and performed intention‐to‐treat analyses if data were available; we otherwise performed available‐case analyses. We investigated attrition rates, for example, dropouts, losses to follow‐up, and withdrawals, and critically appraised issues of missing data. We did not impute missing data. </p> </section> <section id="CD007360-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>We identified heterogeneity (inconsistency) through visual inspection of the forest plots to assess the amount of overlap of CIs, and the I<sup>2</sup> statistic, which quantifies inconsistency across studies to assess the impact of heterogeneity in the meta‐analysis (<a href="./references#CD007360-bbs2-0060" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>; <a href="./references#CD007360-bbs2-0061" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.)2003;327(7414):557‐60. ">Higgins 2003</a>); we interpreted the I<sup>2</sup> statistic as follows (<a href="./references#CD007360-bbs2-0048" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>): </p> <p> <ul id="CD007360-list-0016"> <li> <p>0% to 40%: may not be important;</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>When we found heterogeneity, we attempted to determine possible reasons for it by examining individual study and subgroup characteristics. </p> </section> <section id="CD007360-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to obtain study protocols to assess for selective outcome reporting. If we included 10 or more studies contributing in a meta‐analysis, we used funnel plots to assess small‐study effects (<a href="./references#CD007360-bbs2-0090" title="SterneJA , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). Several explanations can be offered for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials), and publication bias. Therefore, we interpreted results carefully. </p> </section> <section id="CD007360-sec-0057"> <h4 class="title">Data synthesis</h4> <p>We summarised data using a random‐effects model. We interpreted random‐effects meta‐analyses with due consideration of the whole distribution of effects. In addition, we performed statistical analyses according to the statistical guidelines contained in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007360-bbs2-0048" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). For dichotomous outcomes, we used the Mantel‐Haenszel method; for continuous outcomes, we used the inverse variance method. We used Review Manager 5 to perform analyses (<a href="./references#CD007360-bbs2-0084" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> </section> <section id="CD007360-sec-0058"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to possibly introduce clinical heterogeneity, and planned to carry out subgroup analyses with investigation of interactions. </p> <p> <ul id="CD007360-list-0017"> <li> <p>Severity of baseline symptoms based on IPSS (0 to 7 = mildly symptomatic; 8 to 19 = moderately symptomatic; 20 to 35 = severely symptomatic). </p> </li> <li> <p>Participant age (less than 65 years versus 65 years and older).</p> </li> </ul> </p> <p>These subgroup analyses were based on the following observations.</p> <p> <ul id="CD007360-list-0018"> <li> <p>Relationship between changes in IPSS and participant global ratings of improvement is influenced by the baseline scores (<a href="./references#CD007360-bbs2-0039" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesK , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154(5):1770‐4. ">Barry 1995</a>). </p> </li> <li> <p>Tolerability of other ABs (as the main comparator) may differ by participant age (<a href="./references#CD007360-bbs2-0070" title="KozminskiMA , WeiJT , NelsonJ , KentDM . Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH). BJU International2015;115(2):308‐16. ">Kozminski 2015</a>; <a href="./references#CD007360-bbs2-0071" title="LeporH . Alpha blockers for the treatment of benign prostatic hyperplasia. Reviews in Urology2007;9(4):181‐90. ">Lepor 2007</a>). </p> </li> </ul> </p> <p>We planned to perform subgroup analyses limited to the primary outcomes.</p> </section> <section id="CD007360-sec-0059"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses limited to the primary outcomes to explore the influence of the following factors (when applicable) on effect sizes. </p> <p> <ul id="CD007360-list-0019"> <li> <p>Restricting the analysis by taking into account risk of bias, by excluding studies at 'high risk' or 'unclear risk' of bias. </p> </li> </ul> </p> <section id="CD007360-sec-0060"> <h5 class="title"><i>'Summary of findings' tables</i> </h5> <p>We presented the certainty of the evidence for each outcome according to the GRADE approach, which takes into account five criteria related to internal validity (risk of bias, inconsistency, imprecision, publication bias) and external validity (directness of results) (<a href="./references#CD007360-bbs2-0056" title='GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , SchünemannHJ , GRADE Working Group. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.)2008;336(7651):995‐8. '>Guyatt 2008</a>). For each comparison, two review authors (ECH, JHJ) independently rated the certainty of the evidence for each outcome as 'high,' 'moderate,' 'low,' or 'very low' using <a href="./references#CD007360-bbs2-0055" title="McMaster University (developed by Evidence Prime). GRADEpro GDT 2015. Version accessed 17 November 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>. We resolved any discrepancies by consensus, or, if needed, by arbitration by a third review author (PD). For each comparison, we presented a summary of the evidence for the main outcomes in the 'Summary of findings' tables, which provides key information about the best estimate of the magnitude of the effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence in effect estimates for each outcome (<a href="./references#CD007360-bbs2-0058" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. ">Guyatt 2011b</a>; <a href="./references#CD007360-bbs2-0089" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007360-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007360-sec-0061"></div> <section id="CD007360-sec-0062"> <h3 class="title">Description of studies</h3> <section id="CD007360-sec-0063"> <h4 class="title">Results of the search</h4> <p>We identified 537 records through electronic database searching, five records in trials registers, and two records in reference lists of reviews. We found no records in the grey literature repository or through handsearching abstract proceedings of relevant meetings from 2015 to 2017. After removal of duplicates, we screened the titles and abstracts of 309 records, and excluded 267 obviously irrelevant records. We screened 42 full‐text articles (34 studies), and excluded 10 records (10 studies) that did not meet the inclusion criteria or were not relevant to the review. Two studies are awaiting classification. We included 22 studies (30 records) in the review. The flow of literature through the assessment process is shown in the PRISMA flowchart (<a href="#CD007360-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007360-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007360-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD007360-sec-0064"> <h4 class="title">Included studies</h4> <p>Details of included studies are presented in the <a href="./references#CD007360-sec-0146" title="">Characteristics of included studies</a> table; <a href="#CD007360-tbl-0005">Table 1</a>; and <a href="#CD007360-tbl-0006">Table 2</a>. </p> <div class="table" id="CD007360-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial period (year to year)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention (duration of follow‐up)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age (± SD; years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean prostate volume (± SD; mL)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IPSS (± SD)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with LUTS with OAB symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50–75 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.61 ± 5.8 (estimated from the figure)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.72 ± 6.96 (estimated from the figure)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre (16 investigational sites)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 50 years, IPSS ≥ 8, Q<sub>max</sub> &lt; 15 mL/s (voided volume ≥ 150 mL), prostate ≥ 20 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg/day for 2 weeks, followed by 50 mg/day for 10 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.0 ± 7.2 (calculated from 95% CI 66.4 to 69.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.0 ± 10.2 (calculated from 95% CI 27.2 to 32.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 ± 5.7 (calculated from 95% CI 14.1 to 16.8)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day for 12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.5 ± 6.8 (calculated from 95% CI 67.0 to 70.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.6 ± 18.1 (calculated from 95% CI 29.5 to 37.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.1 ± 6.18 (calculated from 95% CI 15.7 to 18.5)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>India</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single institution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 45 years, daytime frequency &gt; 8, nocturnal frequency &gt; 2, Q<sub>max</sub> 5–15 mL/s (150 mL voided volume), PVR &lt; 150 mL, IPSS &gt; 13, IPSS bother score &gt; 3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.81 ± 6.45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.31 ± 4.04</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.73 ± 7.33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.95 ± 4.46</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005–2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre (4 centres)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 50 years at first visit, total IPSS ≥ 8, QoL index score ≥ 2 prostate volume ≥ 20 mL, PVR &lt; 100 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.5 ± 5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.2 ± 16.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.8 ± 5.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.9 ± 5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.0 ± 19.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.5 ± 5.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2000–2002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 hospitals in single institute</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>IPSS ≥ 8; Q<sub>max</sub> &lt; 12 mL/s (150 mL voiding);, if prior BPH medication, 1 month washout period </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg/day for first 2 weeks, then 50 mg once daily for 6 weeks then tamsulosin 0.2 mg for 8 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks (additional 8 weeks after cross‐over/no washout)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.6 ± 7.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.9 ± 11.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4 ± 6.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg for 8 weeks then naftopidil 25 mg for 2 weeks, then 50 mg for 6 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.8 ± 9.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.7 ± 9.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.8 ± 7.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single institution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 50–75 years with BPH, IPSS ≥ 13, PSA ≤ 4 ng/mL, Q<sub>max</sub> 5–15 mL/s when urine volume &gt; 150 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.5 ± 5.26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.79 ± 4.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.5 ± 5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.71 ± 4.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Korea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>94 men who had been taking tamsulosin for more than 8 weeks; however, men who persisted &gt; 3 points of OABSS, especially &gt; 2 points of OABSS question 3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day for 8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.0 ± 6.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.8 ± 14.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.9 ± 6.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily for 8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.8 ± 7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.5 ± 22.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.1 ± 7.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2002–2003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre (9 centres)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with BPH/LUTS aged 50–75 years, total IPSS ≥ 13, prostate volume &gt; 20 mL, Q<sub>max</sub> &lt; 15 mL/s, PVR &lt; 60 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.7 ± 5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.1 ± 15.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6 ± 5.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.8 ± 5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.1 ± 17.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.1 ± 5.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009–2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with LUTS/BPH, prostate volume ≥ 20 cm<sup>3</sup>, IPSS ≥ 8, QoL score ≥ 3, clinical diagnosis of BPH, aged ≥ 50 years, no prior treatment for BPH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50–75 mg once/ daily for 2 weeks, then 75 mg once daily for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks (additional 6 weeks after cross‐over, no washout)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.5 ± 5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.7 ± 17.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.6 ± 5.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 2–4 mg twice daily for 2 weeks, then 4 mg twice daily for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.5 ± 5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.8 ± 13.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.6 ± 5.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005–2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre (17 centres)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with LUTS/BPH, aged 51–79 years, IPSS ≥ 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.5 ± 7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.9 ± 15.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0 ± 5.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.2 ± 7.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.4 ± 13.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.8 ± 5.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2012–2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 50 years, total IPSS ≥ 8, IPSS‐QoL score ≥ 3, total OABSS ≥ 3, ≥ 1 urinary urgency episodes/week, prostate volume ≥ 20 mL on transabdominal ultrasonography, Q<sub>max</sub> &lt; 15 mL/s at a voided volume of ≥ 100 mL and PVR &lt; 150 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day for 4 weeks, followed by 75 mg/day for 8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.3 ± 7.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6 ± 14.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 ± 6.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 4 mg/day for 4 weeks, followed by 8 mg/day for 8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.6 ± 7.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.6 ± 16.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.8 ± 6.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2002–2003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with LUTS with BPH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day for 4 weeks then tamsulosin 0.2 mg/day for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28 days (additional 28 days after cross‐over, no washout)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.3 ± 5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.7 ± 13.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.6 ± 7.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day for 4 weeks and naftopidil 50 mg/day 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.2 ± 7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.2 ± 22.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.4 ± 6.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with LUTS secondary to BPH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day for 4 weeks then tamsulosin 0.2 mg for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks: data analysis (4 weeks before cross‐over. 1‐week washout, and additional 4 weeks after cross‐over) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.2 ± 4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6 ± 3.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.7 ± 4.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day for 4 weeks then naftopidil 50 mg for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.5 ± 4.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 ± 2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1 ± 2.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011–2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>India</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged &gt; 50 years, clinical symptoms of BPE, LUTS, with or without raised PVR urine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.9 ± 5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.97 ± 2.53</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.1 ± 5.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.3 ± 2.84</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2007–2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Kobe University School or other collaborating institutions</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with BPH/LUTS, total IPSS 8 points, QoL index 3 points, Q<sub>max</sub> &lt; 15 mL/s, prostate volume 20 mL; either men without history of using any a1‐receptor blocker (hereafter, drug‐naive group) or men who had continued to use tamsulosin 0.2 mg once daily for ≥ 3 months and wanted to switch the medication to another oral drug (hereafter, drug‐switching group). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 consecutive weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.50 ± 6.58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.39 ± 25.96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.56 ± 6.73</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 4 mg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.98 ± 6.69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.24 ± 12.94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.53 ± 5.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010–2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>India</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single institution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with BPH; IPSS &gt; 8 or &gt; 3 points for frequency, nocturia, and urgency on IPSS; prostate volume &gt; 15 mL, or peak flow rate &lt; 10 mL for voided volume &gt; 150 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.06</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.53</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009–2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with OAB and BPH, who met the following criteria and were not administered medication (except herbal preparation) for urinary disorder: IPSS ≥ 2, QoL score ≥ 2, OABSS ≥ 3 (urgency score ≥ 2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks (additional 8 weeks after cross‐over, no washout: authors judged that evaluation without washout period would be feasible) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.7 ± 8.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4 ± 6.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day + solifenacin 5 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.9 ± 8.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.1 ± 5.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2004–2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 50 years, number of nocturia ≥ 2, IPSS ≥ 8, QoL index ≥ 3, residual urine volume &lt; 50 mL (evaluated by ultrasound estimation), maximum voiding flow rate &lt; 15 mL/s (preferably with a urination volume ≥ 150 mL), prostate volume &lt; 50 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6–8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.6 ± 6.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.4 ± 6.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.2 ± 6.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.8 ± 8.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.7 ± 7.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 ± 6.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2007–2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with BPH aged ≥ 50 years, significant LUTS and deteriorated QoL, IPSS ≥ 8, IPSS‐QoL score ≥ 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.0 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5 ± 18.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 ± 7.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 8 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.3 ± 7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.2 ± 21.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.9 ± 5.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>IPSS ≥ 8, Q<sub>max</sub> &lt; 12 mL/s, prostate volume ≥ 15 mL, obstructive (or equivocal) condition on International Continence Society nomogram as assessed in a pressure/flow study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 75 mg once daily for 2 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.5 ± 8.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.7 ± 14.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.4 ± 5.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eviprostat 6 tablets daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.0 ± 6.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.5 ± 15.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.0 ± 6.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2004–2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 centres</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 50 years, IPSS ≥ 8, 2‐day frequency volume chart showing ≥ 1 episode/day of urinary urgency, daytime voiding frequency ≥ 8 episodes/day, night‐time voiding frequency ≥ 1 episode/night, PVR ≤ 50 mL. Men with elevated serum PSA level (&gt; 10 ng/mL) were confirmed as having BPH before the treatment by transrectal ultrasound‐guided prostate sextant biopsies. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.1 ± 8.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6 ± 12.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2 ± 5.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Propiverine hydrochloride 20 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.9 ± 6.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.3 ± 7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2 ± 7.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 centres</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Men with LUTS aged 50–80 years, IPSS ≥ 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.1 ± 1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.0 ± 3.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4 ± 0.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.5 ± 1.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5 ± 2.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.0 ± 1.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 4 mg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.2 ± 0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3 ± 2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.7 ± 0.7</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BPE: benign prostatic enlargement; BPH: benign prostatic hyperplasia; CI: confidence interval; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; NR: not reported; OAB: overactive bladder; OABSS: overactive bladder symptom score; PSA: prostate‐specific antigen; PVR: postvoid residual; Q<sub>max</sub>: maximum flow rate; QoL: quality of life; s: second; SD: standard deviation. </p> </div> </div> <div class="table" id="CD007360-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants in included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysed (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing trial (n (%))</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50–75 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg/day for 2 weeks, followed by 50 mg/day for 10 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>185/144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (64.8)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg/day for first 2 weeks, then 50 mg once daily for 6 weeks then tamsulosin 0.2 mg for 8 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg for 8 weeks then naftopidil 25 mg for 2 weeks, then 50 mg for 6 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (67.7)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>80/80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 (96.3)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>906/906</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>264</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50–75 mg once for 2 weeks, then 75 mg once daily for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/92</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 2–4 mg twice daily for 2 weeks, then 4 mg twice daily for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (69.6)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (76.8)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg for 4 weeks, then 75 mg for 8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/350</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 4 mg for 4 weeks, then 8 mg for 8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>350</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314 (89.7)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/ 4 weeks, then tamsulosin 0.2 mg/day for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg for 4 weeks, then naftopidil 50 mg/day for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day 4 weeks, then tamsulosin 0.2 mg/day 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day 4 weeks, then naftopidil 50 mg/day 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56/57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 4 mg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112/116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (92.5)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 (91.8)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day + solifenacin 5 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>109/109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 8 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (90.0)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg once daily for 2 weeks, then 50 mg once daily for 2 weeks, and then 75 mg once daily for 2 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eviprostat 6 tablets daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Propiverine hydrochloride 20 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>136/136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 4 mg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 (89.7)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Overall total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interventions: naftopidil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a> did not report </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1086<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>793<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: tamsulosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a> did not report </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>723<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: silodosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>383</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>337 (87.9)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: propiverine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: Eviprostat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2223</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1612 (72.5)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n: number; NR: not reported.</p> <p><sup>a</sup>Two included studies did not report the number of randomised participants (<a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>). </p> <p><sup>b</sup>Four included studies did not report the number of participants who finished trials (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>; <a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>). </p> </div> </div> <section id="CD007360-sec-0065"> <h5 class="title">Source of data</h5> <p>We included 21 published studies and one abstract proceeding (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>). Search of the electronic databases identified 21 published studies. Seventeen studies were published in English, three were published in Japanese (<a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>), and two were published in Chinese (<a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>), which were translated into English by two review authors (MI, RP) or using Google translator. We attempted to contact all corresponding authors of included trials to obtain additional information on study methodology and results, and received replies from three (<a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>; see <a href="./appendices#CD007360-sec-0136">Appendix 2</a>). </p> </section> <section id="CD007360-sec-0066"> <h5 class="title">Study design and settings</h5> <p>We included 17 parallel, RCTs (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>; <a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>; <a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>), and five cross‐over trials (<a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>). Four of 22 studies were reported as 'double‐blinded.' One study blinded participants and investigators (<a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>). Three study were reported to be 'double‐blinded' but it was unclear who was blinded (<a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>). Three studies were open‐label trials (<a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>). The remaining 10 trials had no information regarding blinding. There was one trial with run‐in periods (<a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>). </p> <p>All studies were probably conducted in an outpatient clinic setting. Five studies explicitly stated that the trial was conducted in an outpatient clinic setting (<a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>). All included studies were performed in Asia (Korea, Japan, China, and India). Twelve trials were multicentre (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>; <a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>; <a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a>). The studies were performed from 2002 to 2017. </p> </section> <section id="CD007360-sec-0067"> <h5 class="title">Participants</h5> <p>We included 2223 randomised participants (naftopidil 1086, tamsulosin 723, silodosin 383, propiverine 18, Eviprostat 13), of which 1612 completed the trials (naftopidil 793, tamsulosin 451, silodosin 337, propiverine 18, Eviprostat 13). However, two studies that compared naftopidil to tamsulosin did not report the number of participants randomised to each group (<a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>), and four studies did not report the number of participants who completed the trial in each group (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>; <a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>). All studies included men aged over 40 years. The mean age was 67.8 years, prostate volume was 35.4 mL, and IPSS was 18.3. </p> <p>All studies included participants with LUTS. Three studies included participants with IPSS more than 13 (<a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>). Four studies did not specify the inclusion criteria for LUTS in detail (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>). One study included participants who had been taking tamsulosin for eight weeks; however, participants had persistent overactive bladder symptoms (<a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>). Ten studies used a Q<sub>max</sub> of 15 mL/s as an inclusion criterion (<a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>; <a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>). Major exclusion criteria included LUTS from any cause other than BPH, prior treatment with other BPH medical therapy, recent AUR, raised PSA level suspicious of prostate cancer, history of prostate cancer, or prior prostate‐related surgery. </p> </section> <section id="CD007360-sec-0068"> <h5 class="title">Interventions</h5> <p>All studies administered naftopidil as an oral dose of 25 mg to 75 mg once daily.</p> </section> <section id="CD007360-sec-0069"> <h5 class="title">Comparators</h5> <p>Studies used four different comparators, namely tamsulosin, silodosin, propiverine, and Eviprostat. All comparators were administrated orally. Tamsulosin was administered as an oral dose of 0.2 mg (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>; <a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>), or 0.4 mg once daily (<a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>). One study used tamsulosin 0.2 mg plus solifenacin 5 mg once daily as a comparator (<a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>). Silodosin was administered as an oral dose of 4 mg to 8 mg once daily (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). Propiverine was administered as an oral dose of 20 mg once daily (<a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a>). Eviprostat was administered as an oral dose of six tablets once daily (<a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>). </p> <p>Nine studies had a duration of intervention of 12 weeks (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>; <a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). Six studies followed the participants for four weeks to eight weeks (<a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>; <a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>; <a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a>). <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a> reported 12‐month follow‐up data. For cross‐over trials, two trials reported four weeks' follow‐up (<a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>), one trial reported six weeks' follow‐up (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>), and two trials reported eight weeks' follow‐up (<a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>), before the cross‐over. </p> </section> <section id="CD007360-sec-0070"> <h5 class="title">Comparisons</h5> <p>We included four comparisons in this review: 16 studies compared naftopidil to tamsulosin (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>; <a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>), five studies compared naftopidil to silodosin (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>), one study compared naftopidil to propiverine (<a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>), and one study compared naftopidil to Eviprostat (<a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>). All studies used naftopidil or other ABs as monotherapy. None of the trials compared combination therapy with naftopidil or any 5‐ARIs to combination therapy with other ABs and any 5‐ARIs. </p> </section> <section id="CD007360-sec-0071"> <h5 class="title">Outcomes</h5> <p>We identified all primary outcomes in each of the included studies for four comparisons. Several studies did not report our predefined secondary outcomes. However, we were able to obtain additional information by contact with the study authors (<a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). Given the nature of cross‐over design studies, we assumed they were not applicable to the outcomes of AUR and surgical intervention for LUTS/BPH for the analysis. Other secondary outcomes were reported in at least one of the included studies. </p> </section> <section id="CD007360-sec-0072"> <h5 class="title">Funding sources and conflicts of interest</h5> <p>One study reported no funding source (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>), and three reported the funding source (one supported by National program (<a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>), and two supported by a university (<a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>)). The remaining trials did not mention a funding source. Seven studies reported no conflicts of interest (<a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a>). The remaining studies did not mention conflicts of interest. </p> </section> </section> <section id="CD007360-sec-0073"> <h4 class="title">Excluded studies</h4> <p>We excluded 10 studies (10 records) out of 34 studies (41 records) after evaluation of the full‐text publications. One study was a commentary (<a href="./references#CD007360-bbs2-0023" title="CarsonCC . Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017;197(2):458. ">Carson 2017</a>) and one was a review (<a href="./references#CD007360-bbs2-0026" title="IkemotoI . Benign prostatic hyperplasia: its pathophysiologic characteristics analysed with symptom scores. Tokyo Jikeikai Medical Journal2010;125(4):95‐108. ">Ikemoto 2010</a>). Five studies had an ineligible comparator (<a href="./references#CD007360-bbs2-0025" title="HiroshiT , TakahikoM , KimihikoM , KastuyaN . Comparison of different doses of naftopidil for overactive bladder associated with benign prostatic hyperplasia: a prospective, randomized controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1207. ">Hiroshi 2011</a>; <a href="./references#CD007360-bbs2-0027" title="MaruyamaO , KawachiY , HanazawaK , KoizumiK , YamashitaR , SugimuraS , et al. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled study. International Journal of Urology2006;13(10):1280‐5. ">Maruyama 2006</a>; <a href="./references#CD007360-bbs2-0028" title="SakaiH , IgawaT , OnitaT , FurukawaM , HakariyaT , HayashiM , et al. Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication. Hinyokika Kiyo. Acta Urologica Japonica2011;57(1):7‐13. ">Sakai 2011</a>; <a href="./references#CD007360-bbs2-0029" title="TsuritaniS , NozakiT , OkumuraA , KimuraH , KazamaT . A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily. Urologia Internationalis2010;85(1):80‐7. ">Tsuritani 2010</a>; <a href="./references#CD007360-bbs2-0032" title="YokoyamaT , KumonH , NasuY , TakamotoH , WatanabeT . Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. International Journal of Urology2006;13(7):932‐8. ">Yokoyama 2006</a>). One study had an ineligible study design (<a href="./references#CD007360-bbs2-0024" title="HayashiT , SakaiY , SaitoK , AraiG , HyochiN , SuzukiM , et al. A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2002;48(1):7‐11. ">Hayashi 2002</a>). Two studies had an ineligible study outcome (<a href="./references#CD007360-bbs2-0030" title="YamaguchiO , FukayaY , ShiraiwaY , KanekoS , YachikuS , YasudaK , et al. Clinical evaluation of naftopidil (KT‐611) on urinary obstruction caused by benign prostatic hypertrophy: double‐blind comparative study compared with prazosin hydrochloride. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)1992;8(3):699‐722. ">Yamaguchi 1992</a>; <a href="./references#CD007360-bbs2-0031" title="YamaguchiO , FukayaY , ShiraiwaY , KanekoS , YachikuS , HonmaY , et al. Dose‐dependent effects and clinical usefulness of naftopidil (KT‐611) on urinary obstruction caused by benign prostatic hyperplasia – double‐blind comparative study compared with placebo. Kiso to Rinsho (The Clinical Report)1997;31:1315‐60. ">Yamaguchi 1997</a>). However, since there was the possibility that outcomes of interest were measured but not reported, we contacted the first author of the studies and received replies (see <a href="./appendices#CD007360-sec-0136">Appendix 2</a>). Details of excluded studies are presented in the <a href="./references#CD007360-sec-0147" title="">Characteristics of excluded studies</a> table. </p> <section id="CD007360-sec-0074"> <h5 class="title">Studies awaiting classification</h5> <p>We found two studies awaiting classification, which did not provide usable outcome data (<a href="./references#CD007360-bbs2-0033" title="NCT01203371 . Efficacy and safety study of naftopidil to patients treatment with LUTS. clinicaltrials.gov/ct2/show/NCT01203371 Date first received: 16 September 2010. ">NCT01203371</a>; <a href="./references#CD007360-bbs2-0034" title="NCT01922375 . Clinical trial to evaluate the efficacy and safety of naftopidil in male patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. clinicaltrials.gov/ct2/show/NCT01922375 Date first received: 11 February 2013. ">NCT01922375</a>; see <a href="./references#CD007360-sec-0148" title="">Characteristics of studies awaiting classification</a> table). </p> </section> <section id="CD007360-sec-0075"> <h5 class="title">Ongoing trials</h5> <p>We found no ongoing studies.</p> </section> </section> </section> <section id="CD007360-sec-0076"> <h3 class="title">Risk of bias in included studies</h3> <p>See the 'Risk of bias' table within the <a href="./references#CD007360-sec-0146" title="">Characteristics of included studies</a> table for further details; <a href="#CD007360-fig-0002">Figure 2</a>; and <a href="#CD007360-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD007360-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007360-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD007360-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007360-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007360-sec-0077"> <h4 class="title">Allocation</h4> <section id="CD007360-sec-0078"> <h5 class="title">Random sequence generation</h5> <p> <ul id="CD007360-list-0020"> <li> <p>We rated 11 studies at low risk of bias (<a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>), and three studies at high risk of bias (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>). The remaining studies were at unclear risk of bias. </p> </li> </ul> </p> </section> <section id="CD007360-sec-0079"> <h5 class="title">Allocation concealment</h5> <p> <ul id="CD007360-list-0021"> <li> <p>We rated one study at low risk of bias (<a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>); the remaining studies were at unclear risk of bias. </p> </li> </ul> </p> </section> </section> <section id="CD007360-sec-0080"> <h4 class="title">Blinding</h4> <section id="CD007360-sec-0081"> <h5 class="title">Blinding of participants and personnel</h5> <p> <ul id="CD007360-list-0022"> <li> <p>We rated one study at low risk of bias (<a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>). We judged six studies at high risk of bias (<a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>; <a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>), and the remaining studies at unclear risk of bias. </p> </li> </ul> </p> </section> <section id="CD007360-sec-0082"> <h5 class="title">Blinding of outcome assessment</h5> <p> <ul id="CD007360-list-0023"> <li> <p>Susceptible (subjective: urological symptom scores, QoL, treatment withdrawal for any reason, treatment withdrawal due to adverse events, cardiovascular adverse events, and sexual adverse events) outcomes: we rated three studies at low risk of bias for susceptible (subjective) outcomes (<a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>). We judged two studies at high risk of bias (<a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>), and the remaining studies at unclear risk of bias. </p> </li> <li> <p>Not susceptible (objective: AUR and surgical intervention for LUTS/BPH) outcomes: we rated all studies at low risk of bias for objective outcomes because objective outcomes are unlikely to be affected by lack of blinding. </p> </li> </ul> </p> </section> </section> <section id="CD007360-sec-0083"> <h4 class="title">Incomplete outcome data</h4> <p> <ul id="CD007360-list-0024"> <li> <p>Urological symptom scores and QoL: we rated six studies at low risk of bias (<a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>). We judged eight studies at high risk of bias (<a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>), and the remaining studies at unclear risk of bias. </p> </li> <li> <p>Treatment withdrawal for any reason: we rated 17 studies at low risk of bias (<a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>; <a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>; <a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>), and the remaining at unclear risk of bias. </p> </li> <li> <p>Treatment withdrawal due to adverse events: we rated 15 studies at low risk of bias (<a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>, <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>; <a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a>), and the remaining studies at unclear risk of bias. </p> </li> <li> <p>AUR and surgical intervention for LUTS/BPH: we rated two studies at low risk of bias (<a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>), and the remaining studies at unclear risk of bias. </p> </li> <li> <p>Cardiovascular adverse events: we rated 10 studies at low risk of bias (<a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>), and one study at high risk of bias (<a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>). The remaining studies were at unclear risk of bias. </p> </li> <li> <p>Sexual adverse events: we rated seven studies at low risk of bias (<a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>), and one study at high risk bias (<a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>). The remaining studies were at unclear risk of bias. </p> </li> </ul> </p> </section> <section id="CD007360-sec-0084"> <h4 class="title">Selective reporting</h4> <p> <ul id="CD007360-list-0025"> <li> <p>We rated one study at low risk of bias (<a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>). We judged two studies) at high risk of bias (<a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>), and the remaining studies at unclear risk of bias. </p> </li> </ul> </p> </section> <section id="CD007360-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p> <ul id="CD007360-list-0026"> <li> <p>We rated 13 studies at low risk of bias (<a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a>). We judged four studies at high risk of bias due to clinically important imbalances in baseline characteristics and for selectively enrolling participants who had a poor response to other ABs (<a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). The remaining studies were at unclear risk of bias. </p> </li> </ul> </p> </section> </section> <section id="CD007360-sec-0086"> <h3 class="title" id="CD007360-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD007360-tbl-0001"><b>Summary of findings for the main comparison</b> Naftopidil compared to tamsulosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</a>; <a href="./full#CD007360-tbl-0002"><b>Summary of findings 2</b> Naftopidil compared to silodosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</a>; <a href="./full#CD007360-tbl-0003"><b>Summary of findings 3</b> Naftopidil compared to propiverine (anticholinergic) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</a>; <a href="./full#CD007360-tbl-0004"><b>Summary of findings 4</b> Naftopidil compared to Eviprostat (phytotherapy) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</a> </p> <section id="CD007360-sec-0087"> <h4 class="title">1. Naftopidil versus tamsulosin</h4> <p>See: <a href="./full#CD007360-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD007360-sec-0088"> <h5 class="title">1.1. Urological symptom scores</h5> <p>We included 12 RCTs with 965 participants in the analysis (naftopidil 482, tamsulosin 483) (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>; <a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). We used the final value in four studies (<a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>), and change from baseline in the remaining studies. Naftopidil may have resulted in little to no difference in urological symptom scores (MD 0.47, 95% CI –0.09 to 1.04; I<sup>2</sup> = 17%). We rated the certainty of the evidence as moderate, downgrading for study limitations (<a href="./references#CD007360-fig-0006" title="">Analysis 1.1</a>). The funnel plot showed symmetry thereby suggesting no publication bias (<a href="#CD007360-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD007360-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Naftopidil versus tamsulosin, outcome: 1.1 International Prostate Symptom Score." data-id="CD007360-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Naftopidil versus tamsulosin, outcome: 1.1 International Prostate Symptom Score. </p> </div> </div> </div> </section> <section id="CD007360-sec-0089"> <h5 class="title">1.2. Quality of life</h5> <p>We included 11 RCTs with 878 participants in the analysis (naftopidil 434, tamsulosin 444) (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>; <a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). We used final value in three studies (<a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>), and change from baseline in the remaining studies. Naftopidil may have resulted in little to no difference in QoL (MD 0.11, 95% CI –0.09 to 0.30; I<sup>2</sup> = 52%). We rated the certainty of the evidence as low, downgrading for study limitations, inconsistency, and concerns about publication bias due to funnel plot asymmetry (<a href="./references#CD007360-fig-0007" title="">Analysis 1.2</a>; <a href="#CD007360-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD007360-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Naftopidil versus tamsulosin, outcome: 1.2 International Prostate Symptom Score‐Quality of Life." data-id="CD007360-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Naftopidil versus tamsulosin, outcome: 1.2 International Prostate Symptom Score‐Quality of Life. </p> </div> </div> </div> </section> <section id="CD007360-sec-0090"> <h5 class="title">1.3. Treatment withdrawal for any reason</h5> <p>We included eight RCTs with 668 participants in the analysis (naftopidil 335, tamsulosin 333) (<a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). Naftopidil may have resulted in little to no difference in treatment withdrawal for any reason (RR 0.92, 95% CI 0.64 to 1.34; I<sup>2</sup> = 0%). We rated the certainty of the evidence as low, downgrading for study limitations and imprecision (<a href="./references#CD007360-fig-0008" title="">Analysis 1.3</a>). </p> </section> <section id="CD007360-sec-0091"> <h5 class="title">1.4. Treatment withdrawals due to adverse events</h5> <p>We included nine RCTs with 735 participants in the analysis (naftopidil 366, tamsulosin 369) (<a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). For the cross‐over trials, we used only the number of participants who had been initially randomised due to lack of information about the number of participants in the analysis (<a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>). Naftopidil may have resulted in little to no difference in treatment withdrawal due to adverse events (RR 1.82, 95% CI 0.72 to 4.61; I<sup>2</sup> = 0%). We rated the certainty of the evidence as low downgrading for study limitations and imprecision (<a href="./references#CD007360-fig-0009" title="">Analysis 1.4</a>). </p> </section> <section id="CD007360-sec-0092"> <h5 class="title">1.5. Acute urinary retention</h5> <p>We included three RCTs with 272 participants in the analysis (naftopidil 142, tamsulosin 130) (<a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). We found no events for AUR in two studies (<a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). Naftopidil likely resulted in little to no difference in AUR (RR 0.82, 95% CI 0.23 to 2.86). We rated the certainty of the evidence as moderate, downgrading for imprecision (few events, few participants, and wide CIs) (<a href="./references#CD007360-fig-0010" title="">Analysis 1.5</a>). </p> </section> <section id="CD007360-sec-0093"> <h5 class="title">1.6. Surgical intervention for lower urinary tract symptoms/benign prostatic hyperplasia</h5> <p>We included two RCTs with 171 participants in the analysis (naftopidil 92, tamsulosin 79) (<a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). There were no events for surgical intervention for LUTS/BPH in either group (<a href="./references#CD007360-fig-0011" title="">Analysis 1.6</a>). </p> </section> <section id="CD007360-sec-0094"> <h5 class="title">1.7. Cardiovascular adverse events</h5> <p>We included nine RCTs with 824 participants in the analysis (naftopidil 413, tamsulosin 411) (<a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a>; <a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). For cross‐over trials, we took all measurements from naftopidil periods and all measurements from tamsulosin periods (<a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a>). Naftopidil may have resulted in little to no difference in cardiovascular adverse events (RR 0.97, 95% CI 0.52 to 1.80; I<sup>2</sup> = 14%). We rated the certainty of the evidence as low, downgrading for study limitations and imprecision (<a href="./references#CD007360-fig-0012" title="">Analysis 1.7</a>). </p> </section> <section id="CD007360-sec-0095"> <h5 class="title">1.8. Sexual adverse events</h5> <p>We included five RCTs with 397 participants in the analysis (naftopidil 204, tamsulosin 193) (<a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a>; <a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a>; <a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). Naftopidil may have resulted in little to no difference in sexual adverse events (RR 0.54, 95% CI 0.24 to 1.22; I<sup>2</sup> = 0%). We rated the certainty of the evidence as low, downgrading for study limitations and imprecision (<a href="./references#CD007360-fig-0013" title="">Analysis 1.8</a>). </p> </section> <section id="CD007360-sec-0096"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD007360-sec-0097"> <h5 class="title">Sensitivity analysis</h5> <p>We rated all of the included studies at high or unclear risk of bias and were unable to perform a sensitivity analysis. </p> </section> </section> <section id="CD007360-sec-0098"> <h4 class="title">2. Naftopidil versus silodosin</h4> <p>See: <a href="./full#CD007360-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD007360-sec-0099"> <h5 class="title">2.1. Urological symptom scores</h5> <p>We included five RCTs with 652 participants in the analysis (naftopidil 327, silodosin 325) (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). We used change from baseline. Naftopidil may have resulted in little to no difference in urological symptom scores (MD 1.04, 95% CI –0.78 to 2.85; I<sup>2</sup> = 84%). We rated the certainty of the evidence as low, downgrading for study limitations and inconsistency (<a href="./references#CD007360-fig-0014" title="">Analysis 2.1</a>). </p> </section> <section id="CD007360-sec-0100"> <h5 class="title">2.2. Quality of life</h5> <p>We included five RCTs with 652 participants in the analysis (naftopidil 327, silodosin 325) (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). We used change from baseline. Naftopidil may have resulted in little to no difference in QoL (MD 0.21, 95% CI –0.23 to 0.66; I<sup>2</sup> = 92%). We rated the certainty of the evidence as low, downgrading for study limitations and inconsistency (<a href="./references#CD007360-fig-0015" title="">Analysis 2.2</a>). </p> </section> <section id="CD007360-sec-0101"> <h5 class="title">2.3. Treatment withdrawals for any reason</h5> <p>We included four RCTs with 659 participants in the analysis (naftopidil 325, silodosin 334) (<a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). Naftopidil may have resulted in little to no difference in treatment withdrawal for any reason (RR 0.80, 95% CI 0.52 to 1.23; I<sup>2</sup> = 0%). We rated the certainty of the evidence as low, downgrading for study limitations and imprecision (<a href="./references#CD007360-fig-0016" title="">Analysis 2.3</a>). </p> </section> <section id="CD007360-sec-0102"> <h5 class="title">2.4. Treatment withdrawals due to adverse events</h5> <p>We included five RCTs with 738 participants in the analysis (naftopidil 366, silodosin 372) (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). For the cross‐over trial, we used only the number of participants who had been initially randomised due to lack of information about the number of participants in the analysis (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>). Naftopidil may have resulted in little to no difference in treatment withdrawal due to adverse events (RR 0.72, 95% CI 0.35 to 1.51; I<sup>2</sup> = 0%). We rated the certainty of the evidence as low downgrading for study limitations and imprecision (<a href="./references#CD007360-fig-0017" title="">Analysis 2.4</a>). </p> </section> <section id="CD007360-sec-0103"> <h5 class="title">2.5. Acute urinary retention</h5> <p>We included two RCTs with 180 participants in the analysis (naftopidil 86, silodosin 94) (<a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). There were no events for AUR in either group (<a href="./references#CD007360-fig-0018" title="">Analysis 2.5</a>). </p> </section> <section id="CD007360-sec-0104"> <h5 class="title">2.6. Surgical intervention for lower urinary tract symptoms/benign prostatic hyperplasia</h5> <p>We included two RCTs with 180 participants in the analysis (naftopidil 86, silodosin 94) (<a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). There were no events for surgical intervention for LUTS/BPH in either group (<a href="./references#CD007360-fig-0019" title="">Analysis 2.6</a>). </p> </section> <section id="CD007360-sec-0105"> <h5 class="title">2.7. Cardiovascular adverse events</h5> <p>We included five RCTs with 808 participants in the analysis (naftopidil 397, silodosin 411) (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). For the cross‐over trial, we took all measurements from naftopidil periods and all measurements from silodosin periods (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>). Naftopidil may have resulted in little to no difference in cardiovascular adverse events (RR 0.98, 95% CI 0.39 to 2.44; I<sup>2</sup> = 0%). We rated the certainty of the evidence as low downgrading for study limitations and imprecision (<a href="./references#CD007360-fig-0020" title="">Analysis 2.7</a>). </p> </section> <section id="CD007360-sec-0106"> <h5 class="title">2.8. Sexual adverse events</h5> <p>We included four RCTs with 348 participants in the analysis (naftopidil 172, silodosin 176) (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a>; <a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a>; <a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a>). For the cross‐over trial, we took all measurements from naftopidil periods and all measurements from silodosin periods (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>). Naftopidil likely decreased sexual adverse events (RR 0.15, 95% CI 0.06 to 0.42; I<sup>2</sup> = 0%). Naftopidil would result in 126 fewer sexual adverse events per 1000 men (95% CI 139 fewer to 86 fewer). We rated the certainty of the evidence as moderate, downgrading for study limitations (<a href="./references#CD007360-fig-0021" title="">Analysis 2.8</a>). </p> </section> <section id="CD007360-sec-0107"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD007360-sec-0108"> <h5 class="title">Sensitivity analysis</h5> <p>We rated all of the included studies as high or unclear risk of bias and were unable to perform a sensitivity analysis. </p> </section> </section> <section id="CD007360-sec-0109"> <h4 class="title">3. Naftopidil versus propiverine</h4> <p>See: <a href="./full#CD007360-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD007360-sec-0110"> <h5 class="title">3.1. Urological symptom scores</h5> <p>We included one RCT with 37 participants in the analysis (naftopidil 19, propiverine 18) (<a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a>). Naftopidil may have resulted in little to no difference in urological symptom scores (MD –2.80, 95% CI –6.99 to 1.39). We rated the certainty of the evidence as low, downgrading for study limitations and imprecision (<a href="./references#CD007360-fig-0022" title="">Analysis 3.1</a>). </p> </section> <section id="CD007360-sec-0111"> <h5 class="title">3.2. Quality of life</h5> <p>We included one RCT with 37 participants in the analysis (naftopidil 19, propiverine 18) (<a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a>). Naftopidil may have resulted in little to no difference in QoL (MD 0.10, 95% CI –0.56 to 0.76). We rated the certainty of the evidence as low, downgrading for study limitations and imprecision (<a href="./references#CD007360-fig-0023" title="">Analysis 3.2</a>). </p> </section> <section id="CD007360-sec-0112"> <h5 class="title">3.3. Treatment withdrawals for any reason; treatment withdrawals due to adverse events; acute urinary retention; surgical intervention for lower urinary tract symptoms/benign prostatic hyperplasia; cardiovascular adverse events; sexual adverse events </h5> <p>We found no studies that reported these outcomes.</p> </section> <section id="CD007360-sec-0113"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD007360-sec-0114"> <h5 class="title">Sensitivity analysis</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD007360-sec-0115"> <h4 class="title">4. Naftopidil versus Eviprostat</h4> <p>See: <a href="./full#CD007360-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD007360-sec-0116"> <h5 class="title">4.1. Urological symptom scores</h5> <p>We included one RCT with 49 participants in the analysis (naftopidil 36, Eviprostat 13) (<a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>). Naftopidil likely reduced urological symptom scores (MD –6.30, 95% CI –9.46 to –3.14). We rated the certainty of the evidence as moderate, downgrading for study limitations (<a href="./references#CD007360-fig-0024" title="">Analysis 4.1</a>). </p> </section> <section id="CD007360-sec-0117"> <h5 class="title">4.2. Quality of life</h5> <p>We included one RCT with 49 participants in the analysis (naftopidil 36, Eviprostat 13) (<a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>). Naftopidil likely increased QoL (MD –1.50, 95% CI –2.36 to –0.64). We rated the certainty of the evidence as moderate, downgrading for study limitations (<a href="./references#CD007360-fig-0025" title="">Analysis 4.2</a>). </p> </section> <section id="CD007360-sec-0118"> <h5 class="title">4.3. Treatment withdrawals for any reason</h5> <p>We included one RCT with 49 participants in the analysis (naftopidil 36, Eviprostat 13) (<a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>). There were no events for treatment withdrawal for any reason (<a href="./references#CD007360-fig-0026" title="">Analysis 4.3</a>). </p> </section> <section id="CD007360-sec-0119"> <h5 class="title">4.4. Treatment withdrawals due to adverse events</h5> <p>We included one RCT with 49 participants in the analysis (naftopidil 36, Eviprostat 13) (<a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a>). There were no events for treatment withdrawal due to adverse events (<a href="./references#CD007360-fig-0027" title="">Analysis 4.4</a>). </p> </section> <section id="CD007360-sec-0120"> <h5 class="title">4.5. Acute urinary retention; surgical intervention for lower urinary tract symptoms/benign prostatic hyperplasia; cardiovascular adverse events; sexual adverse events </h5> <p>We found no studies that reported these outcomes.</p> </section> <section id="CD007360-sec-0121"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD007360-sec-0122"> <h5 class="title">Sensitivity analysis</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007360-sec-0123" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007360-sec-0123">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007360-sec-0187">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007360-sec-0123"></div> <section id="CD007360-sec-0124"> <h3 class="title" id="CD007360-sec-0124">Summary of main results</h3> <p>We included 22 unique studies with 2223 randomised participants across four comparisons for short‐term follow‐up (up to 12 weeks). We found no longer‐term data. </p> <p>We were unable to compare naftopidil to placebo. The only available study did not report on any outcome relevant to this review (<a href="./references#CD007360-bbs2-0031" title="YamaguchiO , FukayaY , ShiraiwaY , KanekoS , YachikuS , HonmaY , et al. Dose‐dependent effects and clinical usefulness of naftopidil (KT‐611) on urinary obstruction caused by benign prostatic hyperplasia – double‐blind comparative study compared with placebo. Kiso to Rinsho (The Clinical Report)1997;31:1315‐60. ">Yamaguchi 1997</a>). </p> <p>Compared to tamsulosin, naftopidil may have had a similar effect on urological symptom scores, QoL, and treatment withdrawals for any reason (primary outcomes). It may have had a similar effect on treatment withdrawals due to adverse event, AUR, surgical intervention for LUTS/BPH, cardiovascular adverse events, and sexual adverse events (secondary outcomes). </p> <p>Findings were similar when comparing naftopidil to silodosin with the exception of sexual adverse events, which were substantially reduced by naftopidil. Naftopidil resulted in 123 fewer sexual adverse events per 1000 men (95% CI 139 fewer to 80 fewer) compared to silodosin. </p> <p>The body of evidence comparing naftopidil to other ABs was limited. Compared to propiverine, naftopidil may have had similar effects on urological symptom scores and QoL. We found no studies that reported other outcomes. Compared to Eviprostat, naftopidil likely resulted in a clinically important reduction in urological symptom scores and improved QoL. There were no treatment withdrawals for any reason or due to adverse events. </p> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD007360-sec-0125"> <h3 class="title" id="CD007360-sec-0125">Overall completeness and applicability of evidence</h3> <p>In this review update, we used up‐to‐date Cochrane methods and added 16 news trials. Despite a large body of evidence informing this review, the following issues deserve consideration. </p> <p> <ul id="CD007360-list-0027"> <li> <p>In contrast to the previous version of this review, we identified one trial comparing naftopidil to placebo (<a href="./references#CD007360-bbs2-0031" title="YamaguchiO , FukayaY , ShiraiwaY , KanekoS , YachikuS , HonmaY , et al. Dose‐dependent effects and clinical usefulness of naftopidil (KT‐611) on urinary obstruction caused by benign prostatic hyperplasia – double‐blind comparative study compared with placebo. Kiso to Rinsho (The Clinical Report)1997;31:1315‐60. ">Yamaguchi 1997</a>). We could not use the study results because the study did not report on any outcomes relevant to this review. This information was confirmed by direct communication with the study investigators. </p> </li> <li> <p>Our ability to assess the longer‐term outcomes of naftopidil compared to other drugs was limited given that all trials had a short duration of follow‐up of 12 weeks or less. Therefore, we were unable to assess the longer‐term efficacy and adverse effects of naftopidil. </p> </li> <li> <p>Aside from three studies that used tamsulosin 0.4 mg (<a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>), most studies comparing naftopidil to tamsulosin 0.2 mg, which is lower than the recommended dose in Western countries and is based on a lower mean body size in Asian countries. Therefore, general applicability of this body of evidence to non‐Asian men is uncertain. </p> </li> <li> <p>We were unable to determine the effect of naftopidil on AUR or surgical interventions due to the lack of events in the included studies. This related to the short follow‐up period. Additional information may have to be drawn from longer‐term observational studies. </p> </li> <li> <p>Although ABs such as naftopidil are commonly used in combination with 5‐ARIs, we found no eligible studies. </p> </li> </ul> </p> </section> <section id="CD007360-sec-0126"> <h3 class="title" id="CD007360-sec-0126">Quality of the evidence</h3> <p>We consistently downgraded the certainty of the evidence by one or two levels to moderate or low. The most common reasons for downgrading were study limitations (issues surrounding allocation concealment, blinding, and incomplete outcome data), clinically important inconsistency (with high I<sup>2</sup> values, which we were unable to explain through secondary analyses), and imprecision (wide CIs that crossed the assumed threshold of clinically important difference or few events, or both). We also detected some cases of potential publication bias due to the observed funnel plot asymmetry. </p> </section> <section id="CD007360-sec-0127"> <h3 class="title" id="CD007360-sec-0127">Potential biases in the review process</h3> <p>Despite a comprehensive search strategy without any publication or language restrictions, it is possible that we may have missed relevant publications. A majority of studies originated from Japan including other Asian countries (India, China, Korea). However, this regional problem might not be resolved in future study because naftopidil was only approved these countries to treat men with BPH. It is possible that some, in particular negative studies, were published in non‐indexed journals or presented at local meetings only and therefore may have escaped our search. All Japanese and Chinese literature were translated into English by two review authors (MI, RP) with appropriate language skills. We used Google translator to double check the translated data. However, the lack of human double‐data abstraction may be considered a potential source of bias. We investigated reporting bias using funnel plots, which showed no symmetry for IPSS (<a href="#CD007360-fig-0004">Figure 4</a>) and asymmetry for QoL in naftopidil and tamsulosin comparison arms (<a href="#CD007360-fig-0005">Figure 5</a>). We attempted to contact all the study authors on several occasions seeking feedback. While we received additional information from three study authors, others did not reply. This may represent a source of bias. For cross‐over trials, we tried to extract the data from first period (before cross‐over), as if the study were a parallel‐group trial, in accordance with <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007360-bbs2-0064" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). However, two cross‐over trials used the event rate to report individual adverse events, which may result in a unit of analysis error (double counting) (<a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a>; <a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a>). For other cross‐over trials, we used the number of participants initially randomised as a more conservative approach. </p> </section> <section id="CD007360-sec-0128"> <h3 class="title" id="CD007360-sec-0128">Agreements and disagreements with other studies or reviews</h3> <p>Two systematic reviews and meta‐analyses reported that naftopidil had a similar effect on urological symptom scores and bladder outlet obstruction indices compared to other ABs (<a href="./references#CD007360-bbs2-0053" title="FuscoF , PalmieriA , FicarraV , GiannariniG , NovaraG , LongoN , et al. α1‐Blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta‐analysis of urodynamic studies. European Urology2016;69(6):1091‐101. ">Fusco 2016</a>; <a href="./references#CD007360-bbs2-0095" title="YuanJQ , MaoC , WongSY , YangZY , FuXH , DaiXY , et al. Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta‐analysis. Medicine (Baltimore)2015;94(27):e974. ">Yuan 2015</a>). Along with a previous Cochrane systematic review results (<a href="./references#CD007360-bbs2-0096" title="GarimellaPS , FinkHA , MacdonaldR , WiltTJ . Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007360.pub2] ">Garimella 2009</a>), one systematic review reported that naftopidil had comparable efficacy to tamsulosin and silodosin (<a href="./references#CD007360-bbs2-0042" title="CastiglioneF , BenigniF , BrigantiA , SaloniaA , VillaL , NiniA , et al. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. Current Medical Research and Opinion2014;30(4):719‐32. ">Castiglione 2014</a>). Overall adverse events were reported as 2% to 15%, which was comparable to tamsulosin (<a href="./references#CD007360-bbs2-0042" title="CastiglioneF , BenigniF , BrigantiA , SaloniaA , VillaL , NiniA , et al. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. Current Medical Research and Opinion2014;30(4):719‐32. ">Castiglione 2014</a>). The incidence of sexual adverse events was less than compared to silodosin (<a href="./references#CD007360-bbs2-0042" title="CastiglioneF , BenigniF , BrigantiA , SaloniaA , VillaL , NiniA , et al. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. Current Medical Research and Opinion2014;30(4):719‐32. ">Castiglione 2014</a>). However, both reviews only included RCTs from Japan and those published in English language. In addition, no meta‐analysis was reported and the authors did not rate the certainty of the evidence (<a href="./references#CD007360-bbs2-0042" title="CastiglioneF , BenigniF , BrigantiA , SaloniaA , VillaL , NiniA , et al. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. Current Medical Research and Opinion2014;30(4):719‐32. ">Castiglione 2014</a>; <a href="./references#CD007360-bbs2-0096" title="GarimellaPS , FinkHA , MacdonaldR , WiltTJ . Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007360.pub2] ">Garimella 2009</a>). This updated Cochrane Review used rigorous methodology, exhaustive literature search, and assessment of the certainty of the evidence using GRADE, thereby providing the most reliable evidence summary. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007360-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007360-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007360-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007360-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Naftopidil versus tamsulosin, outcome: 1.1 International Prostate Symptom Score." data-id="CD007360-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Naftopidil versus tamsulosin, outcome: 1.1 International Prostate Symptom Score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Naftopidil versus tamsulosin, outcome: 1.2 International Prostate Symptom Score‐Quality of Life." data-id="CD007360-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Naftopidil versus tamsulosin, outcome: 1.2 International Prostate Symptom Score‐Quality of Life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Naftopidil versus tamsulosin, Outcome 1 International Prostate Symptom Score." data-id="CD007360-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Naftopidil versus tamsulosin, Outcome 1 International Prostate Symptom Score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Naftopidil versus tamsulosin, Outcome 2 International Prostate Symptom Score‐Quality of Life." data-id="CD007360-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Naftopidil versus tamsulosin, Outcome 2 International Prostate Symptom Score‐Quality of Life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Naftopidil versus tamsulosin, Outcome 3 Treatment withdrawals for any reason." data-id="CD007360-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Naftopidil versus tamsulosin, Outcome 3 Treatment withdrawals for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Naftopidil versus tamsulosin, Outcome 4 Treatment withdrawals due to adverse events." data-id="CD007360-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Naftopidil versus tamsulosin, Outcome 4 Treatment withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Naftopidil versus tamsulosin, Outcome 5 Acute urinary retention." data-id="CD007360-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Naftopidil versus tamsulosin, Outcome 5 Acute urinary retention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Naftopidil versus tamsulosin, Outcome 6 Surgical intervention." data-id="CD007360-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Naftopidil versus tamsulosin, Outcome 6 Surgical intervention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Naftopidil versus tamsulosin, Outcome 7 Cardiovascular adverse events." data-id="CD007360-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Naftopidil versus tamsulosin, Outcome 7 Cardiovascular adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Naftopidil versus tamsulosin, Outcome 8 Sexual adverse events." data-id="CD007360-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Naftopidil versus tamsulosin, Outcome 8 Sexual adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Naftopidil versus silodosin, Outcome 1 International Prostate Symptom Score." data-id="CD007360-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Naftopidil versus silodosin, Outcome 1 International Prostate Symptom Score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Naftopidil versus silodosin, Outcome 2 International Prostate Symptom Score‐Quality of Life." data-id="CD007360-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Naftopidil versus silodosin, Outcome 2 International Prostate Symptom Score‐Quality of Life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Naftopidil versus silodosin, Outcome 3 Treatment withdrawals for any reason." data-id="CD007360-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Naftopidil versus silodosin, Outcome 3 Treatment withdrawals for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Naftopidil versus silodosin, Outcome 4 Treatment withdrawals due to adverse events." data-id="CD007360-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Naftopidil versus silodosin, Outcome 4 Treatment withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Naftopidil versus silodosin, Outcome 5 Acute urinary retention." data-id="CD007360-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Naftopidil versus silodosin, Outcome 5 Acute urinary retention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Naftopidil versus silodosin, Outcome 6 Surgical intervention." data-id="CD007360-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Naftopidil versus silodosin, Outcome 6 Surgical intervention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Naftopidil versus silodosin, Outcome 7 Cardiovascular adverse events." data-id="CD007360-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Naftopidil versus silodosin, Outcome 7 Cardiovascular adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Naftopidil versus silodosin, Outcome 8 Sexual adverse events." data-id="CD007360-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Naftopidil versus silodosin, Outcome 8 Sexual adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Naftopidil versus propiverine, Outcome 1 International Prostate Symptom Score." data-id="CD007360-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Naftopidil versus propiverine, Outcome 1 International Prostate Symptom Score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Naftopidil versus propiverine, Outcome 2 International Prostate Symptom Score‐Quality of Life." data-id="CD007360-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Naftopidil versus propiverine, Outcome 2 International Prostate Symptom Score‐Quality of Life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Naftopidil versus Eviprostat, Outcome 1 International Prostate Symptom Score." data-id="CD007360-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Naftopidil versus Eviprostat, Outcome 1 International Prostate Symptom Score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Naftopidil versus Eviprostat, Outcome 2 International Prostate Symptom Score‐Quality of Life." data-id="CD007360-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Naftopidil versus Eviprostat, Outcome 2 International Prostate Symptom Score‐Quality of Life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Naftopidil versus Eviprostat, Outcome 3 Treatment withdrawals for any reason." data-id="CD007360-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Naftopidil versus Eviprostat, Outcome 3 Treatment withdrawals for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007360-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/urn:x-wiley:14651858:media:CD007360:CD007360-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_t/tCD007360-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Naftopidil versus Eviprostat, Outcome 4 Treatment withdrawals due to adverse events." data-id="CD007360-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Naftopidil versus Eviprostat, Outcome 4 Treatment withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/media/CDSR/CD007360/image_n/nCD007360-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007360-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Naftopidil compared to tamsulosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Naftopidil compared to tamsulosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with lower urinary tract symptoms suggesting benign prostatic hyperplasia </p> <p><b>Setting:</b> likely outpatients </p> <p><b>Intervention:</b> naftopidil </p> <p><b>Comparator:</b> tamsulosin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with tamsulosin</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with naftopidil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urological symptom scores</b><br/> assessed with: IPSS<br/> Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/> Follow‐up: 4–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>965<br/> (12 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean urological symptom scores ranged from 9.2 to 10.7 (from 4 studies) and mean change of urological symptom scores ranged from –9.8 to –3.3 (from 8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.47 higher<br/> (0.09 lower to 1.04 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> assessed with: IPSS‐Quality of Life<br/> Scale from: 0 (best: delighted) to 6 (worst: terrible)<br/> Follow‐up: 4–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>878<br/> (11 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life ranged from 2.7 to 3.1 (from 3 studies) and mean change of quality of life ranged from –2.75 to –0.7 (from 8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.11 higher<br/> (0.09 lower to 0.30 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawals for any reason</b><br/> Follow‐up: 4–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>668<br/> (8 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.92</b><br/> (0.64 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 fewer per 1000<br/> (32 fewer to 31 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular adverse events</b><br/> Follow‐up: 4–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>824<br/> (9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.97</b><br/> (0.52 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 fewer per 1000<br/> (28 fewer to 47 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Sexual adverse events</b><br/> Follow‐up: 4–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>397<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.54</b><br/> (0.24 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 fewer per 1000<br/> (43 fewer to 13 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for study limitations: unclear or high risk of bias in one or more domains. </p> <p><sup>b</sup>Downgraded by one level for inconsistency: moderate‐to‐substantial heterogeneity. </p> <p><sup>c</sup>Downgraded by one level for imprecision: confidence interval crossed assumed threshold of clinically important difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Naftopidil compared to tamsulosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007360-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Naftopidil compared to silodosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Naftopidil compared to silodosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with lower urinary tract symptoms suggesting benign prostatic hyperplasia </p> <p><b>Setting:</b> likely outpatients </p> <p><b>Intervention:</b> naftopidil </p> <p><b>Comparator:</b> silodosin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with silodosin</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with naftopidil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urological symptom scores</b><br/> Assessed with: IPSS<br/> Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/> Follow‐up: 6–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>652<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of urological symptom scores ranged from –8.6 to –4.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.04 higher<br/> (0.78 lower to 2.85 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> Assessed with: IPSS‐QoL<br/> Scale from: 0 (best: delighted) to 6 (worst: terrible)<br/> Follow‐up: 6–12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>652<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of quality of life ranged from –2.0 to –0.98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.21 higher<br/> (0.23 lower to 0.66 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawals for any reason</b> </p> <p>Follow‐up: 8–12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>659<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.80</b><br/> (0.52 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 fewer per 1000<br/> (62 fewer to 30 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular adverse events</b> </p> <p>Follow‐up: 6–12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>808<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.98</b><br/> (0.39 to 2.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (15 fewer to 35 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Sexual adverse events</b> </p> <p>Follow‐up: 6–12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>348<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.15</b><br/> (0.06 to 0.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126 fewer per 1000<br/> (139 fewer to 86 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>IPSS‐QoL:</b> International Prostate Symptom Score – Quality of Life; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for study limitations: unclear or high risk of bias in one or more domains. </p> <p><sup>b</sup>Downgraded by one level for inconsistency: substantial heterogeneity. </p> <p><sup>c</sup>Downgraded by one level in imprecision: confidence interval crossed assumed threshold of clinically important difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Naftopidil compared to silodosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007360-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Naftopidil compared to propiverine (anticholinergic) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Naftopidil compared to propiverine (anticholinergic) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with lower urinary tract symptoms suggesting benign prostatic hyperplasia </p> <p><b>Setting:</b> likely outpatients </p> <p><b>Intervention:</b> naftopidil </p> <p><b>Comparato</b> r<b>:</b> propiverine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with propiverine</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with naftopidil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urological symptom scores</b><br/> assessed with: IPSS<br/> Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/> Follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of urological symptom scores was –2.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.8 lower<br/> (6.99 lower to 1.39 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> assessed with: IPSS‐QoL<br/> Scale from: 0 (best: delighted) to 6 (worst: terrible)<br/> Follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of quality of life was –1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.1 higher<br/> (0.56 lower to 0.76 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawals for any reason</b><sup>c</sup><br/> follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular adverse events</b><sup>c</sup><br/> follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Sexual adverse events</b><sup>c</sup><br/> follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>IPSS‐QoL:</b> International Prostate Symptom Score – Quality of Life; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for study limitations: unclear risk of selection, performance, detection, and reporting bias. </p> <p><sup>b</sup>Downgraded by one level for imprecision: confidence interval crossed assumed threshold of clinically important difference of IPSS 3 and quality of life 0.5. </p> <p><sup>c</sup>Treatment withdrawal due to any reasons; cardiovascular adverse events; and sexual adverse events: no available data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Naftopidil compared to propiverine (anticholinergic) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007360-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Naftopidil compared to Eviprostat (phytotherapy) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Naftopidil compared to Eviprostat (phytotherapy) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with lower urinary tract symptoms suggesting benign prostatic hyperplasia </p> <p><b>Setting:</b> likely outpatients </p> <p><b>Intervention:</b> naftopidil </p> <p><b>Comparator:</b> Eviprostat </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Eviprostat</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with Naftopidil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urological symptom scores</b><br/> assessed with: IPSS<br/> Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/> Follow‐up: mean 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of urological symptom scores was 0.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 6.3 lower<br/> (9.46 lower to 3.14 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> assessed with: IPSS‐QoL<br/> Scale from: 0 (best: delighted) to 6 (worst: terrible)<br/> Follow‐up: mean 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of quality of life was 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.5 lower<br/> (2.36 lower to 0.64 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawals for any reason</b><br/> Follow‐up: mean 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR approximately 1 with wide CI</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawals due to adverse events</b><br/> Follow‐up: mean 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR approximately 1 with wide CI</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular adverse events</b><sup>c</sup><br/> Follow‐up: mean 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Sexual adverse events</b><sup>c</sup><br/> Follow‐up: mean 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>IPSS‐QoL:</b> International Prostate Symptom Score – Quality of Life; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for study limitations: unclear or high risk of bias in one or more domains. </p> <p><sup>b</sup>Downgraded by two level for imprecision: RR approximately 1 with wide confidence interval and no events. </p> <p><sup>c</sup>Cardiovascular adverse events and sexual adverse events: no available data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Naftopidil compared to Eviprostat (phytotherapy) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007360-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial period (year to year)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention (duration of follow‐up)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age (± SD; years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean prostate volume (± SD; mL)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IPSS (± SD)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with LUTS with OAB symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50–75 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.61 ± 5.8 (estimated from the figure)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.72 ± 6.96 (estimated from the figure)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre (16 investigational sites)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 50 years, IPSS ≥ 8, Q<sub>max</sub> &lt; 15 mL/s (voided volume ≥ 150 mL), prostate ≥ 20 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg/day for 2 weeks, followed by 50 mg/day for 10 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.0 ± 7.2 (calculated from 95% CI 66.4 to 69.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.0 ± 10.2 (calculated from 95% CI 27.2 to 32.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 ± 5.7 (calculated from 95% CI 14.1 to 16.8)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day for 12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.5 ± 6.8 (calculated from 95% CI 67.0 to 70.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.6 ± 18.1 (calculated from 95% CI 29.5 to 37.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.1 ± 6.18 (calculated from 95% CI 15.7 to 18.5)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>India</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single institution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 45 years, daytime frequency &gt; 8, nocturnal frequency &gt; 2, Q<sub>max</sub> 5–15 mL/s (150 mL voided volume), PVR &lt; 150 mL, IPSS &gt; 13, IPSS bother score &gt; 3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.81 ± 6.45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.31 ± 4.04</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.73 ± 7.33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.95 ± 4.46</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005–2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre (4 centres)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 50 years at first visit, total IPSS ≥ 8, QoL index score ≥ 2 prostate volume ≥ 20 mL, PVR &lt; 100 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.5 ± 5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.2 ± 16.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.8 ± 5.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.9 ± 5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.0 ± 19.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.5 ± 5.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2000–2002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 hospitals in single institute</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>IPSS ≥ 8; Q<sub>max</sub> &lt; 12 mL/s (150 mL voiding);, if prior BPH medication, 1 month washout period </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg/day for first 2 weeks, then 50 mg once daily for 6 weeks then tamsulosin 0.2 mg for 8 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks (additional 8 weeks after cross‐over/no washout)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.6 ± 7.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.9 ± 11.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4 ± 6.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg for 8 weeks then naftopidil 25 mg for 2 weeks, then 50 mg for 6 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.8 ± 9.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.7 ± 9.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.8 ± 7.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single institution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 50–75 years with BPH, IPSS ≥ 13, PSA ≤ 4 ng/mL, Q<sub>max</sub> 5–15 mL/s when urine volume &gt; 150 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.5 ± 5.26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.79 ± 4.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.5 ± 5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.71 ± 4.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Korea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>94 men who had been taking tamsulosin for more than 8 weeks; however, men who persisted &gt; 3 points of OABSS, especially &gt; 2 points of OABSS question 3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day for 8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.0 ± 6.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.8 ± 14.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.9 ± 6.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily for 8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.8 ± 7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.5 ± 22.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.1 ± 7.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2002–2003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre (9 centres)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with BPH/LUTS aged 50–75 years, total IPSS ≥ 13, prostate volume &gt; 20 mL, Q<sub>max</sub> &lt; 15 mL/s, PVR &lt; 60 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.7 ± 5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.1 ± 15.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6 ± 5.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.8 ± 5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.1 ± 17.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.1 ± 5.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009–2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with LUTS/BPH, prostate volume ≥ 20 cm<sup>3</sup>, IPSS ≥ 8, QoL score ≥ 3, clinical diagnosis of BPH, aged ≥ 50 years, no prior treatment for BPH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50–75 mg once/ daily for 2 weeks, then 75 mg once daily for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks (additional 6 weeks after cross‐over, no washout)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.5 ± 5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.7 ± 17.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.6 ± 5.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 2–4 mg twice daily for 2 weeks, then 4 mg twice daily for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.5 ± 5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.8 ± 13.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.6 ± 5.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005–2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre (17 centres)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with LUTS/BPH, aged 51–79 years, IPSS ≥ 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.5 ± 7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.9 ± 15.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0 ± 5.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.2 ± 7.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.4 ± 13.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.8 ± 5.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2012–2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 50 years, total IPSS ≥ 8, IPSS‐QoL score ≥ 3, total OABSS ≥ 3, ≥ 1 urinary urgency episodes/week, prostate volume ≥ 20 mL on transabdominal ultrasonography, Q<sub>max</sub> &lt; 15 mL/s at a voided volume of ≥ 100 mL and PVR &lt; 150 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day for 4 weeks, followed by 75 mg/day for 8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.3 ± 7.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6 ± 14.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 ± 6.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 4 mg/day for 4 weeks, followed by 8 mg/day for 8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.6 ± 7.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.6 ± 16.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.8 ± 6.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2002–2003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with LUTS with BPH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day for 4 weeks then tamsulosin 0.2 mg/day for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28 days (additional 28 days after cross‐over, no washout)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.3 ± 5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.7 ± 13.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.6 ± 7.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day for 4 weeks and naftopidil 50 mg/day 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.2 ± 7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.2 ± 22.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.4 ± 6.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with LUTS secondary to BPH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day for 4 weeks then tamsulosin 0.2 mg for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks: data analysis (4 weeks before cross‐over. 1‐week washout, and additional 4 weeks after cross‐over) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.2 ± 4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6 ± 3.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.7 ± 4.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day for 4 weeks then naftopidil 50 mg for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.5 ± 4.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 ± 2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1 ± 2.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011–2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>India</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged &gt; 50 years, clinical symptoms of BPE, LUTS, with or without raised PVR urine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.9 ± 5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.97 ± 2.53</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.1 ± 5.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.3 ± 2.84</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2007–2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Kobe University School or other collaborating institutions</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with BPH/LUTS, total IPSS 8 points, QoL index 3 points, Q<sub>max</sub> &lt; 15 mL/s, prostate volume 20 mL; either men without history of using any a1‐receptor blocker (hereafter, drug‐naive group) or men who had continued to use tamsulosin 0.2 mg once daily for ≥ 3 months and wanted to switch the medication to another oral drug (hereafter, drug‐switching group). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 consecutive weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.50 ± 6.58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.39 ± 25.96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.56 ± 6.73</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 4 mg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.98 ± 6.69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.24 ± 12.94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.53 ± 5.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010–2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>India</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single institution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with BPH; IPSS &gt; 8 or &gt; 3 points for frequency, nocturia, and urgency on IPSS; prostate volume &gt; 15 mL, or peak flow rate &lt; 10 mL for voided volume &gt; 150 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.06</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.53</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009–2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with OAB and BPH, who met the following criteria and were not administered medication (except herbal preparation) for urinary disorder: IPSS ≥ 2, QoL score ≥ 2, OABSS ≥ 3 (urgency score ≥ 2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks (additional 8 weeks after cross‐over, no washout: authors judged that evaluation without washout period would be feasible) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.7 ± 8.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4 ± 6.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day + solifenacin 5 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.9 ± 8.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.1 ± 5.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2004–2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 50 years, number of nocturia ≥ 2, IPSS ≥ 8, QoL index ≥ 3, residual urine volume &lt; 50 mL (evaluated by ultrasound estimation), maximum voiding flow rate &lt; 15 mL/s (preferably with a urination volume ≥ 150 mL), prostate volume &lt; 50 mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6–8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.6 ± 6.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.4 ± 6.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.2 ± 6.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.8 ± 8.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.7 ± 7.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 ± 6.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2007–2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with BPH aged ≥ 50 years, significant LUTS and deteriorated QoL, IPSS ≥ 8, IPSS‐QoL score ≥ 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.0 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5 ± 18.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 ± 7.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 8 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.3 ± 7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.2 ± 21.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.9 ± 5.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>IPSS ≥ 8, Q<sub>max</sub> &lt; 12 mL/s, prostate volume ≥ 15 mL, obstructive (or equivocal) condition on International Continence Society nomogram as assessed in a pressure/flow study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 75 mg once daily for 2 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.5 ± 8.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.7 ± 14.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.4 ± 5.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eviprostat 6 tablets daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.0 ± 6.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.5 ± 15.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.0 ± 6.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2004–2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 centres</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 50 years, IPSS ≥ 8, 2‐day frequency volume chart showing ≥ 1 episode/day of urinary urgency, daytime voiding frequency ≥ 8 episodes/day, night‐time voiding frequency ≥ 1 episode/night, PVR ≤ 50 mL. Men with elevated serum PSA level (&gt; 10 ng/mL) were confirmed as having BPH before the treatment by transrectal ultrasound‐guided prostate sextant biopsies. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.1 ± 8.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6 ± 12.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2 ± 5.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Propiverine hydrochloride 20 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.9 ± 6.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.3 ± 7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2 ± 7.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 centres</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Men with LUTS aged 50–80 years, IPSS ≥ 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.1 ± 1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.0 ± 3.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4 ± 0.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.5 ± 1.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5 ± 2.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.0 ± 1.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 4 mg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.2 ± 0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3 ± 2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.7 ± 0.7</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>BPE: benign prostatic enlargement; BPH: benign prostatic hyperplasia; CI: confidence interval; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; NR: not reported; OAB: overactive bladder; OABSS: overactive bladder symptom score; PSA: prostate‐specific antigen; PVR: postvoid residual; Q<sub>max</sub>: maximum flow rate; QoL: quality of life; s: second; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007360-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants in included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysed (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing trial (n (%))</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50–75 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0002" title="GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS . Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271). Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23‐27; Paris. 2004. GotohM , KamihiraO , KinukawaT , OnoY , OhshimaS , OrigasaH . Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. British Journal of Urology International2005;96(4):581‐6. MatsukawaY , GotohM , KamihiraS , OnoY , OhshimaS . Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin. Journal of Urology2005;173(4):461‐2. ">Gotoh 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg/day for 2 weeks, followed by 50 mg/day for 10 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>185/144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0003" title="GriwanMS , KarthikeyanYR , KumarM , SinghBJ , SinghSK . Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urology Annals2014;6(3):181‐6. ">Griwan 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0004" title="HanyuS , HatanoA , NishiyamaT , ObaraK , TakahashiK . A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica2010;56(9):489‐94. ">Hanyu 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (64.8)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0005" title="IkemotoI , KiyotaH , OhishiY , AbeK , GotoH , KishimotoK , et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two‐drug crossover study. International Journal of Urology2003;10(11):587‐94. ">Ikemoto 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg/day for first 2 weeks, then 50 mg once daily for 6 weeks then tamsulosin 0.2 mg for 8 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg for 8 weeks then naftopidil 25 mg for 2 weeks, then 50 mg for 6 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (67.7)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0006" title="JuXB , WuHF , SuJT . The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue [National Journal of Andrology]2002;8(4):286‐8. ">Ju 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>80/80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 (96.3)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>906/906</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>264</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0009" title="MasudaM , JinzaS , MasukoH , AsakuraT , HashibaT . Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo. Acta Urologica Japonica2012;58(12):671‐8. ">Masuda 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50–75 mg once for 2 weeks, then 75 mg once daily for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/92</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 2–4 mg twice daily for 2 weeks, then 4 mg twice daily for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (69.6)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0010" title="MasumoriN , TsukamotoT , IwasawaA , FuruyaR , SonodaT , MoriM , et al. Ejaculatory disorders caused by alpha‐1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urologia Internationalis2009;83(1):49‐54. ">Masumori 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (76.8)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0011" title="MatsukawaY , FunahashiY , TakaiS , MajimaT , OgawaT , NaritaH , et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). Journal of Urology2017; Vol. 197, issue 2:452‐8. ">Matsukawa 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg for 4 weeks, then 75 mg for 8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/350</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 4 mg for 4 weeks, then 8 mg for 8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>350</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314 (89.7)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0012" title="MomoseH , HosokawaY , KishinoT , OnoT , OyamaN . Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today (Barcelona, Spain : 1998)2007;43:1‐10. ">Momose 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/ 4 weeks, then tamsulosin 0.2 mg/day for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg for 4 weeks, then naftopidil 50 mg/day for 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0013" title="NishinoY , MasueT , MiwaK , TakahashiY , IshiharaS , DeguchiT . Comparison of two alpha1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. British Journal of Urology International2006;97(4):747‐51, discussion 751. ">Nishino 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day 4 weeks, then tamsulosin 0.2 mg/day 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day 4 weeks, then naftopidil 50 mg/day 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0015" title="ShirakawaT , HaraguchiT , MatsumotoM , MorishitaS , MinayoshiK , MiyazakiJ , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology2010;76(3):S106. ShirakawaT , HaraguchiT , MatsumotoY , TakedaM , MorishitaS , MinayoshiK , et al. A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. International Urogynecology Journal and Pelvic Floor Dysfunction2011;22:S1209. ShirakawaT , HaraguchiT , ShigemuraK , MorishitaS , MinayoshiK , MiyazakiJ , et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. International Journal of Urology2013;20(9):903‐10. ">Shirakawa 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56/57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 4 mg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112/116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (92.5)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0016" title="SinghI , GuptaA , AgrawalV , JoshiM . A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia. UroToday International Journal2013;6(2):art 17. ">Singh 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 (91.8)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg/day + solifenacin 5 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0019" title="IgarashiT , ItoA , OkawaM , AshikariD , ObinataD , SakumaT , et al. Clinical efficacies and impacts on sexual function of alpha‐1a/d selective blockers in patients with benign prostatic hyperplasia. Neurourology and Urodynamics2011;30(6):1148‐9. TakahashiS , YamaguchiK , Sakura Clinical Study Grp. Treatment of benign prostatic hyperplasia and aging: impacts of alpha‐1 blockers on sexual function. Journal of Mens Health2011;8:S25‐8. YamaguchiK , AokiY , YoshikawaT , HachiyaT , SaitoT , TakahashiS . Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. International Journal of Urology2013;20(12):1234‐8. ">Yamaguchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 75 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>109/109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 8 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (90.0)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0020" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an alpha‐blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology2004;11(7):501‐9. ">Yamanishi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 25 mg once daily for 2 weeks, then 50 mg once daily for 2 weeks, and then 75 mg once daily for 2 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eviprostat 6 tablets daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007360-bbs2-0021" title="YokoyamaT , HaraR , KondoN , FujiiT , JoY , MiyajiY . Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581). Journal of Urology2009;181(4):568. YokoyamaT , UematsuK , WatanabeT , SasakiK , KumonH , NagaiA , et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scandinavian Journal of Urology and Nephrology2009;43(4):307‐14. ">Yokoyama 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Propiverine hydrochloride 20 mg/day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD007360-bbs2-0022" title="YokoyamaT , HaraR , FukumotoK , FujiiT , JoY , MiyajiY , et al. Effects of three types of alpha‐1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. International Journal of Urology2011;18(3):225‐30. ">Yokoyama 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naftopidil 50 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>136/136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 4 mg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 (89.7)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Overall total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interventions: naftopidil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a> did not report </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1086<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>793<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: tamsulosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a> did not report </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>723<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: silodosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>383</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>337 (87.9)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: propiverine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: Eviprostat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (100)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2223</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1612 (72.5)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>n: number; NR: not reported.</p> <p><sup>a</sup>Two included studies did not report the number of randomised participants (<a href="./references#CD007360-bbs2-0017" title="UbH , UtsunomiyaN , MatsumotoK , TsunemoriH , MugurumaK , KawakitaM , et al. A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. Acta Urologica Japonica2016;62(7):341‐7. ">Ub 2016</a>; <a href="./references#CD007360-bbs2-0018" title="UkimuraO , KanazawaM , FujiharaA , KamoiK , OkiharaK , MikiT . Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. International Journal of Urology2008;15(12):1049‐54. ">Ukimura 2008</a>). </p> <p><sup>b</sup>Four included studies did not report the number of participants who finished trials (<a href="./references#CD007360-bbs2-0001" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S152‐4. ">Fujihara 2010</a>; <a href="./references#CD007360-bbs2-0007" title="KwonSY , LeeKS , YooTK , ChungJI , LeeJY , HongJH , et al. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi‐institutional study. Urology2018;111:145‐50. KwonSY , SeoYJ , LeeKS . Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi‐institutional study. International Journal of Urology2017;24(Suppl 1):4‐149. ">Kwon 2018</a>; <a href="./references#CD007360-bbs2-0008" title="LiN‐C , WuS‐L , JinJ , QiuS‐P , KongC‐Z , SongY‐S , et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]2007;45(14):947‐50. ">Li 2007</a>; <a href="./references#CD007360-bbs2-0014" title="PerumalC , ChowdhuryPS , AnanthakrishnanN , NayakP , GurumurthyS . A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urology Annals2015;7(1):74‐8. ">Perumal 2015</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/full#CD007360-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007360-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Naftopidil versus tamsulosin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 International Prostate Symptom Score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐0.09, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 International Prostate Symptom Score‐Quality of Life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.09, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment withdrawals for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.64, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Treatment withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [0.72, 4.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Acute urinary retention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.23, 2.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Surgical intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Cardiovascular adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.52, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Sexual adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.24, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Naftopidil versus tamsulosin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007360-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Naftopidil versus silodosin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 International Prostate Symptom Score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [‐0.78, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 International Prostate Symptom Score‐Quality of Life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.23, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment withdrawals for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.52, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Treatment withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.35, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Acute urinary retention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Surgical intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Cardiovascular adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.39, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Sexual adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.06, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Naftopidil versus silodosin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007360-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Naftopidil versus propiverine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 International Prostate Symptom Score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 International Prostate Symptom Score‐Quality of Life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Naftopidil versus propiverine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007360-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Naftopidil versus Eviprostat</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 International Prostate Symptom Score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 International Prostate Symptom Score‐Quality of Life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment withdrawals for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Treatment withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Naftopidil versus Eviprostat</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007360.pub3/references#CD007360-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007360.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007360-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007360-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD007360-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD007360-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007360-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007360\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007360\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007360\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007360\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007360\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007360.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007360.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007360.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007360.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007360.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718582627"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007360.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718582630"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007360.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd3dcab29f401',t:'MTc0MDcxODU4My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 